

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>The role of tumor microenvironment in resistance to... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-326/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-326" />
    
            <meta name="description" content="Read the original article in full on F1000Research: The role of tumor microenvironment in resistance to anti-angiogenic therapy" />
    
            <meta name="og:title" content="F1000Research Article: The role of tumor microenvironment in resistance to anti-angiogenic therapy.">
            <meta name="og:description" content="Read the latest article version by Shaolin Ma, Sunila Pradeep, Wei Hu, Dikai Zhang, Robert Coleman, Anil Sood, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12716">
            <meta name="article-id" content="11771">
            <meta name="dc.title" content="The role of tumor microenvironment in resistance to anti-angiogenic therapy">
            <meta name="dc.description" content="Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. Over the last decade, several mechanisms have been identified to decipher the emergence of resistance. There is a multitude of changes within the tumor microenvironment (TME) in response to anti-angiogenic therapy that offers new therapeutic opportunities. In this review, we compile results from contemporary studies related to adaptive changes in the TME in the development of resistance to anti-angiogenic therapy. These include preclinical models of emerging resistance, dynamic changes in hypoxia signaling and stromal cells during treatment, and novel strategies to overcome resistance by targeting the TME.">
            <meta name="dc.subject" content="tumor microenvironment, anti-angiogenic therapy, drug resistance, MET signaling  ">
            <meta name="dc.creator" content="Ma, Shaolin">
            <meta name="dc.creator" content="Pradeep, Sunila">
            <meta name="dc.creator" content="Hu, Wei">
            <meta name="dc.creator" content="Zhang, Dikai">
            <meta name="dc.creator" content="Coleman, Robert">
            <meta name="dc.creator" content="Sood, Anil">
            <meta name="dc.date" content="2018/03/15">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11771.1">
            <meta name="dc.source" content="F1000Research 2018 7:326">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="tumor microenvironment">
            <meta name="prism.keyword" content="anti-angiogenic therapy">
            <meta name="prism.keyword" content="drug resistance">
            <meta name="prism.keyword" content="MET signaling  ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/03/15">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="326">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11771.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-326">
            <meta name="citation_title" content="The role of tumor microenvironment in resistance to anti-angiogenic therapy">
            <meta name="citation_abstract" content="Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. Over the last decade, several mechanisms have been identified to decipher the emergence of resistance. There is a multitude of changes within the tumor microenvironment (TME) in response to anti-angiogenic therapy that offers new therapeutic opportunities. In this review, we compile results from contemporary studies related to adaptive changes in the TME in the development of resistance to anti-angiogenic therapy. These include preclinical models of emerging resistance, dynamic changes in hypoxia signaling and stromal cells during treatment, and novel strategies to overcome resistance by targeting the TME.">
            <meta name="citation_description" content="Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. Over the last decade, several mechanisms have been identified to decipher the emergence of resistance. There is a multitude of changes within the tumor microenvironment (TME) in response to anti-angiogenic therapy that offers new therapeutic opportunities. In this review, we compile results from contemporary studies related to adaptive changes in the TME in the development of resistance to anti-angiogenic therapy. These include preclinical models of emerging resistance, dynamic changes in hypoxia signaling and stromal cells during treatment, and novel strategies to overcome resistance by targeting the TME.">
            <meta name="citation_keywords" content="tumor microenvironment, anti-angiogenic therapy, drug resistance, MET signaling  ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Shaolin Ma">
            <meta name="citation_author_institution" content="Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author_institution" content="Reproductive Medicine Research Center, Department of Gynecology and Obstetrics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong province, China">
            <meta name="citation_author" content="Sunila Pradeep">
            <meta name="citation_author_institution" content="Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author" content="Wei Hu">
            <meta name="citation_author_institution" content="Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author" content="Dikai Zhang">
            <meta name="citation_author_institution" content="Reproductive Medicine Research Center, Department of Gynecology and Obstetrics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong province, China">
            <meta name="citation_author" content="Robert Coleman">
            <meta name="citation_author_institution" content="Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author" content="Anil Sood">
            <meta name="citation_author_institution" content="Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author_institution" content="Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author_institution" content="Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_publication_date" content="2018/03/15">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="326">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11771.1">
            <meta name="citation_firstpage" content="326">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-326/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-326.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12716 /> <input type=hidden id=articleId name=articleId value=11771 /> <input type=hidden id=xmlUrl value="/articles/7-326/v1/xml"/> <input type=hidden id=xmlFileName value="-7-326-v1.xml"> <input type=hidden id=article_uuid value=1fb7effe-a190-42fc-ab40-6ba735f025f1 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="The role of tumor microenvironment in resistance to anti-angiogenic therapy"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11771.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11771.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-326"
  },
  "headline": "The role of tumor microenvironment in resistance to anti-angiogenic therapy",
  "datePublished": "2018-03-15T13:49:06",
  "dateModified": "2018-03-15T13:49:06",
  "author": [
    {
      "@type": "Person",
      "name": "Shaolin Ma"
    },    {
      "@type": "Person",
      "name": "Sunila Pradeep"
    },    {
      "@type": "Person",
      "name": "Wei Hu"
    },    {
      "@type": "Person",
      "name": "Dikai Zhang"
    },    {
      "@type": "Person",
      "name": "Robert Coleman"
    },    {
      "@type": "Person",
      "name": "Anil Sood"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. Over the last decade, several mechanisms have been identified to decipher the emergence of resistance. There is a multitude of changes within the tumor microenvironment (TME) in response to anti-angiogenic therapy that offers new therapeutic opportunities. In this review, we compile results from contemporary studies related to adaptive changes in the TME in the development of resistance to anti-angiogenic therapy. These include preclinical models of emerging resistance, dynamic changes in hypoxia signaling and stromal cells during treatment, and novel strategies to overcome resistance by targeting the TME."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-326.html",
            "name": "The role of tumor microenvironment in resistance to anti-angiogenic..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> The role of tumor microenvironment in resistance to anti-angiogenic... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12716 data-id=11771 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11771.1" data-recommended="" data-doi="10.12688/f1000research.11771.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-326/v1/pdf?article_uuid=1fb7effe-a190-42fc-ab40-6ba735f025f1" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11771-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11771-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11771-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ma S, Pradeep S, Hu W <em>et al.</em> The role of tumor microenvironment in resistance to anti-angiogenic therapy [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):326 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11771.1" target=_blank>https://doi.org/10.12688/f1000research.11771.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11771-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11771 id=track-article-signin-11771 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11771?target=/articles/7-326.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12716 /> <input name=articleId type=hidden value=11771 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>The role of tumor microenvironment in resistance to anti-angiogenic therapy</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Shaolin Ma<a href="https://orcid.org/0000-0002-3368-8054" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3368-8054</div><sup>1,2</sup>,&nbsp;</span><span class="">Sunila Pradeep<sup>1</sup>,&nbsp;</span><span class="">Wei Hu<sup>1</sup>,&nbsp;</span><span class="">Dikai Zhang<sup>2</sup>,&nbsp;</span><span class="">Robert Coleman<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:asood@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Anil Sood</span></a><a href="https://orcid.org/0000-0003-4242-1762" target=_blank id=author-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4242-1762</div><sup>1,3,4</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Shaolin Ma<a href="http://orcid.org/0000-0002-3368-8054" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3368-8054</div><sup>1,2</sup>,&nbsp;</span><span class="">Sunila Pradeep<sup>1</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Wei Hu<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Dikai Zhang<sup>2</sup>,&nbsp;</span><span class="">Robert Coleman<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:asood@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Anil Sood</span></a><a href="http://orcid.org/0000-0003-4242-1762" target=_blank id=mauthor-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4242-1762</div><sup>1,3,4</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 15 Mar 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11771.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>2</sup> Reproductive Medicine Research Center, Department of Gynecology and Obstetrics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong province, China<br/> <sup>3</sup> Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>4</sup> Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <p> <div class=margin-bottom> Shaolin Ma <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Sunila Pradeep <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Wei Hu <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Dikai Zhang <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Robert Coleman <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Anil Sood <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=31563-31676></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=1180-31677></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. Over the last decade, several mechanisms have been identified to decipher the emergence of resistance. There is a multitude of changes within the tumor microenvironment (TME) in response to anti-angiogenic therapy that offers new therapeutic opportunities. In this review, we compile results from contemporary studies related to adaptive changes in the TME in the development of resistance to anti-angiogenic therapy. These include preclinical models of emerging resistance, dynamic changes in hypoxia signaling and stromal cells during treatment, and novel strategies to overcome resistance by targeting the TME. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> tumor microenvironment, anti-angiogenic therapy, drug resistance, MET signaling </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Anil Sood (<a href="mailto:asood@mdanderson.org">asood@mdanderson.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Anil Sood </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> RLC has received grant funding from Genentech, Merck, Janssen, Clovis, AZ, and Abbvie and serves on the scientific steering committee as an investigator for Tesaro, Clovis, AZ, and Abbvie. AKS serves on the advisory board for Kiyatec and has received research funding from M-Trap. The other authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> Portions of this work were supported by the National Institutes of Health (P50 CA217685, P50 CA098258, CA177909, and R35 CA209904), the Frank McGraw Memorial Chair in Cancer Research, the Ann Rife Cox Chair in Gynecology, the American Cancer Society Research Professor Award, and the Institutional Core Grant (CA16672) to the MD Anderson Cancer Center from the National Institutes of Health. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Ma S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ma S, Pradeep S, Hu W <em>et al.</em> The role of tumor microenvironment in resistance to anti-angiogenic therapy [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):326 (<a href="https://doi.org/10.12688/f1000research.11771.1" target=_blank>https://doi.org/10.12688/f1000research.11771.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 15 Mar 2018, <b>7</b>(F1000 Faculty Rev):326 (<a href="https://doi.org/10.12688/f1000research.11771.1" target=_blank>https://doi.org/10.12688/f1000research.11771.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 15 Mar 2018, <b>7</b>(F1000 Faculty Rev):326 (<a href="https://doi.org/10.12688/f1000research.11771.1" target=_blank>https://doi.org/10.12688/f1000research.11771.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d12245e247>Introduction</h2><p class="" id=d12245e250>Angiogenesis is well recognized as an important step in the growth and progression of many tumor types<sup><a href="#ref-1">1</a></sup>. Over the last 15 years, anti-angiogenic therapy has become an effective modality for cancer therapy. Several vascular endothelial growth factor/receptor (VEGF/R) inhibitors have been approved by the US Food and Drug Administration for various solid tumors, including metastatic colorectal cancer (mCRC), metastatic renal cell cancer, metastatic gastric cancer, non-small-cell lung cancer, recurrent/metastatic cervical cancer, recurrent ovarian cancer, and glioblastoma multiforme (GBM). Although improvements in objective response and progression-free survival (PFS) have been seen, the impact of anti-angiogenic therapy on patient overall survival (OS) is limited (<a href="#T1">Table 1</a>) because of a host of factors, including the induction of resistance<sup><a href="#ref-2">2</a></sup>. The modes of resistance to angiogenesis inhibitors, mechanisms of acquired or intrinsic resistance, and strategies for overcoming resistance have been discussed (see <a href="#ref-3">3</a>–<a href="#ref-5">5</a>). Meanwhile, new mechanisms and therapies for anti-angiogenic resistance have emerged over the last 3–5 years. Evidence suggests that changes in the tumor microenvironment (TME) play a critical role in such adaptation<sup><a href="#ref-6">6</a></sup>. This review focuses mainly on the role of the TME in response and resistance to anti-angiogenic therapy (<a href="#f1">Figure 1</a>), and novel strategies to overcome resistance by targeting the TME are also discussed.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Survival data of phase II/III clinical trials with anti-angiogenic therapy in last 3 years.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d12245e289 class=n-a></a><thead><a name=d12245e291 class=n-a></a><tr><a name=d12245e293 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e294 class=n-a></a>Tumor type</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e297 class=n-a></a>Study regimen</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e300 class=n-a></a>Number<br class=br>of<br class=br>enrolled<br class=br>patients</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e309 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e312 class=n-a></a>PFS</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e315 class=n-a></a>OS</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e319 class=n-a></a>Phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e322 class=n-a></a>Main finding</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12245e325 class=n-a></a>Reference</th></tr></thead><tbody><a name=d12245e329 class=n-a></a><tr><a name=d12245e331 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e332 class=n-a></a>Platinum-<br class=br>sensitive<br class=br>recurrent<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e341 class=n-a></a>Paclitaxel and carboplatin<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e348 class=n-a></a>674</td><td colspan=1 rowspan=1 valign=top><a name=d12245e351 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e354 class=n-a></a>10.4: 13.8 months<br class=br>HR = 0.63<br class=br>95% CI 0.53–0.74<br class=br><i>p</i> &lt;0.0001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e365 class=n-a></a>37.3: 42.2 months<br class=br>HR = 0.83<br class=br>95% CI 0.68–1.01<br class=br><i>P</i> = 0.056</td><td colspan=1 rowspan=1 valign=top><a name=d12245e377 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e380 class=n-a></a>Adding bevacizumab to<br class=br>chemotherapy prolongs<br class=br>OS, but there is no<br class=br>statistical significance</td><td colspan=1 rowspan=1 valign=top><a name=d12245e389 class=n-a></a><a href="#ref-22">22</a></td></tr><tr><a name=d12245e393 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e394 class=n-a></a>Platinum-<br class=br>sensitive/<br class=br>resistant<br class=br>recurrent<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e405 class=n-a></a>Pegylated liposomal doxorubicin plus<br class=br>placebo<br class=br>versus<br class=br>plus trebananib</td><td colspan=1 rowspan=1 valign=top><a name=d12245e414 class=n-a></a>223</td><td colspan=1 rowspan=1 valign=top><a name=d12245e417 class=n-a></a>Ang-1<br class=br>Ang-2</td><td colspan=1 rowspan=1 valign=top><a name=d12245e422 class=n-a></a>7.2: 7.6 months<br class=br>HR = 0.92<br class=br>95% CI 0.68–1.24<br class=br><i>p</i> = 0.57</td><td colspan=1 rowspan=1 valign=top><a name=d12245e433 class=n-a></a>17.0: 19.4 months<br class=br>HR = 0.94<br class=br>95% CI 0.64–1.39<br class=br><i>p</i> = 0.76</td><td colspan=1 rowspan=1 valign=top><a name=d12245e445 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e448 class=n-a></a>Trebananib demonstrates<br class=br>anti-cancer activity but<br class=br>does not improve PFS<br class=br>or OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e457 class=n-a></a><a href="#ref-23">23</a></td></tr><tr><a name=d12245e461 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e462 class=n-a></a>Recurrent<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e467 class=n-a></a>Paclitaxel plus placebo<br class=br>versus<br class=br>plus trebananib</td><td colspan=1 rowspan=1 valign=top><a name=d12245e474 class=n-a></a>461</td><td colspan=1 rowspan=1 valign=top><a name=d12245e477 class=n-a></a>Ang-1<br class=br>Ang-2</td><td colspan=1 rowspan=1 valign=top><a name=d12245e482 class=n-a></a>5.4: 7.2 months<br class=br>HR = 0.66<br class=br>95% CI 0.57–0.77<br class=br><i>p</i> &lt;0.0001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e493 class=n-a></a>17.3: 19.0 months<br class=br>HR = 0.86<br class=br>95% CI 0.69–1.08<br class=br><i>p</i> = 0.19</td><td colspan=1 rowspan=1 valign=top><a name=d12245e505 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e508 class=n-a></a>Adding trebananib to<br class=br>paclitaxel improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e513 class=n-a></a><a href="#ref-24">24</a></td></tr><tr><a name=d12245e517 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e518 class=n-a></a>Platinum-<br class=br>sensitive<br class=br>recurrent<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e527 class=n-a></a>Gemcitabine and carboplatin alone<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e534 class=n-a></a>484</td><td colspan=1 rowspan=1 valign=top><a name=d12245e537 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e540 class=n-a></a>8.4: 12.4 months<br class=br>HR = 0.48<br class=br>95% CI 0.39–0.61<br class=br>Long-rank <i>p</i> &lt;0.0001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e552 class=n-a></a>32.9: 33.6 months<br class=br>HR = 0.95<br class=br>95% CI 0.77–1.18<br class=br>Long-rank <i>p</i> = 0.65</td><td colspan=1 rowspan=1 valign=top><a name=d12245e565 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e568 class=n-a></a>Adding bevacizumab to<br class=br>chemotherapy statistically<br class=br>significantly improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e575 class=n-a></a><a href="#ref-25">25</a>,<a href="#ref-26">26</a></td></tr><tr><a name=d12245e582 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e583 class=n-a></a>Platinum-<br class=br>resistant<br class=br>recurrent<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e592 class=n-a></a>Paclitaxel/topotecan/pegylated<br class=br>liposomal doxorubicin alone<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e601 class=n-a></a>361</td><td colspan=1 rowspan=1 valign=top><a name=d12245e604 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e607 class=n-a></a>3.4: 6.7 months<br class=br>HR = 0.48<br class=br>95% CI 0.38–0.60<br class=br><i>p</i> &lt;0.001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e618 class=n-a></a>13.3: 16.6 months<br class=br>HR = 0.85<br class=br>95% CI 0.66–1.08<br class=br><i>p</i> &lt;0.174</td><td colspan=1 rowspan=1 valign=top><a name=d12245e630 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e633 class=n-a></a>Adding bevacizumab to<br class=br>chemotherapy statistically<br class=br>significantly improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e640 class=n-a></a><a href="#ref-27">27</a></td></tr><tr><a name=d12245e645 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e646 class=n-a></a>Newly<br class=br>diagnosed<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e653 class=n-a></a>Carboplatin/paclitaxel alone<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e660 class=n-a></a>1,528</td><td colspan=1 rowspan=1 valign=top><a name=d12245e663 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e666 class=n-a></a>16.3: 19.4 months<br class=br>HR = 0.93<br class=br>95% CI 0.83–1.05<br class=br>Long-rank <i>p</i> = 0.25</td><td colspan=1 rowspan=1 valign=top><a name=d12245e678 class=n-a></a>48.6: 48.8 months<br class=br>HR = 0.99<br class=br>95% CI 0.85–1.14<br class=br>Long-rank <i>p</i> = 0.85</td><td colspan=1 rowspan=1 valign=top><a name=d12245e691 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e694 class=n-a></a>Adding bevacizumab to<br class=br>platinum-based therapy<br class=br>does not improve OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e701 class=n-a></a><a href="#ref-28">28</a></td></tr><tr><a name=d12245e705 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e706 class=n-a></a>Relapsed<br class=br>platinum-<br class=br>sensitive<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e715 class=n-a></a>Placebo alongside chemotherapy<br class=br>and then placebo only maintenance<br class=br>versus<br class=br>cediranib alongside chemotherapy<br class=br>then cediranib maintenance</td><td colspan=1 rowspan=1 valign=top><a name=d12245e726 class=n-a></a>486</td><td colspan=1 rowspan=1 valign=top><a name=d12245e729 class=n-a></a>VEGFR1–3</td><td colspan=1 rowspan=1 valign=top><a name=d12245e732 class=n-a></a>8.7: 11.0 months<br class=br>HR = 0.56<br class=br>95% CI 0.44–0.72<br class=br><i>p</i> &lt;0.0001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e743 class=n-a></a>21.0: 26.3 months<br class=br>HR = 0.77<br class=br>95% CI 0.55–1.07<br class=br><i>p</i> = 0.11</td><td colspan=1 rowspan=1 valign=top><a name=d12245e755 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e758 class=n-a></a>Adding cediranib<br class=br>to chemotherapy<br class=br>and continued as<br class=br>maintenance significantly<br class=br>improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e769 class=n-a></a><a href="#ref-29">29</a></td></tr><tr><a name=d12245e773 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e774 class=n-a></a>Recurrent<br class=br>ovarian, tubal,<br class=br>or peritoneal<br class=br>carcinoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e783 class=n-a></a>Bevacizumab<br class=br>versus<br class=br>bevacizumab plus fosbretabulin</td><td colspan=1 rowspan=1 valign=top><a name=d12245e790 class=n-a></a>107</td><td colspan=1 rowspan=1 valign=top><a name=d12245e793 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e796 class=n-a></a>4.8: 7.3 months<br class=br>HR = 0.69<br class=br>90% CI 0.47–1.00<br class=br><i>p</i> = 0.05</td><td colspan=1 rowspan=1 valign=top><a name=d12245e807 class=n-a></a>22.0: 24.6 months<br class=br>HR = 0.85<br class=br>90% CI 0.54–1.34<br class=br><i>p</i> value not provided</td><td colspan=1 rowspan=1 valign=top><a name=d12245e819 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d12245e822 class=n-a></a>Adding fosbretabulin<br class=br>to bevacizumab may<br class=br>enhance its efficacy</td><td colspan=1 rowspan=1 valign=top><a name=d12245e829 class=n-a></a><a href="#ref-30">30</a></td></tr><tr><a name=d12245e833 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e834 class=n-a></a>Advanced<br class=br>ovarian cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e839 class=n-a></a>Carboplatin and paclitaxel plus<br class=br>placebo<br class=br>versus<br class=br>plus nintedanib</td><td colspan=1 rowspan=1 valign=top><a name=d12245e848 class=n-a></a>1,366</td><td colspan=1 rowspan=1 valign=top><a name=d12245e851 class=n-a></a>VEGFR,<br class=br>PDGFR,<br class=br>and FGFR</td><td colspan=1 rowspan=1 valign=top><a name=d12245e858 class=n-a></a>16.6: 17.2 months<br class=br>HR = 0.84<br class=br>95% CI 0.72–0.98<br class=br><i>p</i> = 0.024</td><td colspan=1 rowspan=1 valign=top><a name=d12245e869 class=n-a></a>Pending</td><td colspan=1 rowspan=1 valign=top><a name=d12245e873 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e876 class=n-a></a>Nintedanib in combination<br class=br>with carboplatin and<br class=br>paclitaxel significantly<br class=br>improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e885 class=n-a></a><a href="#ref-31">31</a></td></tr><tr><a name=d12245e889 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e890 class=n-a></a>Advanced<br class=br>cervical cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e895 class=n-a></a>Cisplatin plus paclitaxel/topotecan<br class=br>plus paclitaxel with or without<br class=br>bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e902 class=n-a></a>452</td><td colspan=1 rowspan=1 valign=top><a name=d12245e905 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e908 class=n-a></a>8.2: 5.9 months<br class=br>HR = 0.67<br class=br>95% CI 0.54–0.82<br class=br><i>p</i> = 0.002</td><td colspan=1 rowspan=1 valign=top><a name=d12245e919 class=n-a></a>17.0: 13.3 months<br class=br>HR = 0.71<br class=br>98% CI 0.54–0.95<br class=br><i>p</i> = 0.004</td><td colspan=1 rowspan=1 valign=top><a name=d12245e931 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e934 class=n-a></a>Addition of bevacizumab<br class=br>to combination<br class=br>chemotherapy can<br class=br>improve PFS and OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e943 class=n-a></a><a href="#ref-32">32</a></td></tr><tr><a name=d12245e947 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e948 class=n-a></a>Metastatic<br class=br>or recurrent<br class=br>cervical cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e955 class=n-a></a>Carboplatin and paclitaxel plus<br class=br>placebo<br class=br>versus<br class=br>plus cediranib</td><td colspan=1 rowspan=1 valign=top><a name=d12245e964 class=n-a></a>69</td><td colspan=1 rowspan=1 valign=top><a name=d12245e967 class=n-a></a>VEGFR1–3</td><td colspan=1 rowspan=1 valign=top><a name=d12245e970 class=n-a></a>6.7: 8.1 months<br class=br>HR = 0.58<br class=br>80% CI 0.40–0.85<br class=br><i>p</i> = 0.032</td><td colspan=1 rowspan=1 valign=top><a name=d12245e981 class=n-a></a>14.8: 13.6 months<br class=br>HR = 0.94<br class=br>80% CI 0.65–1.36<br class=br><i>p</i> = 0.42</td><td colspan=1 rowspan=1 valign=top><a name=d12245e993 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d12245e996 class=n-a></a>Adding cediranib to<br class=br>carboplatin and paclitaxel<br class=br>improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1003 class=n-a></a><a href="#ref-33">33</a></td></tr><tr><a name=d12245e1008 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1009 class=n-a></a>Advanced<br class=br>non-squamous<br class=br>non-small-cell<br class=br>lung cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1018 class=n-a></a>Bevacizumab plus docetaxel<br class=br>versus<br class=br>docetaxel alone</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1025 class=n-a></a>100</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1028 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1031 class=n-a></a>4.4: 3.4 months<br class=br>HR = 0.71<br class=br>95% CI 0.47–1.09<br class=br><i>p</i> = 0.058</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1042 class=n-a></a>13.1: 11.0 months<br class=br>HR = 0.74<br class=br>95% CI 0.46–1.19<br class=br><i>p</i> = 0.11</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1054 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1057 class=n-a></a>Adding bevacizumab to<br class=br>docetaxel improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1062 class=n-a></a><a href="#ref-34">34</a></td></tr><tr><a name=d12245e1066 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1067 class=n-a></a>Advanced<br class=br>or recurrent<br class=br>non-squamous<br class=br>non-small-cell<br class=br>lung cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1078 class=n-a></a>Carboplatin/paclitaxel alone<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1085 class=n-a></a>276</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1088 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1091 class=n-a></a>6.5: 9.2 months<br class=br>HR = 0.40<br class=br>95% CI 0.29–0.54<br class=br><i>p</i> &lt;0.001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1102 class=n-a></a>17.7: 24.3 months<br class=br>HR = 0.68<br class=br>95% CI 0.50–0.93<br class=br><i>p</i> = 0.0154</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1114 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1117 class=n-a></a>Adding bevacizumab to<br class=br>carboplatin/paclitaxel is<br class=br>well tolerated and shows<br class=br>a treatment benefit</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1126 class=n-a></a><a href="#ref-35">35</a></td></tr><tr><a name=d12245e1130 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1131 class=n-a></a>Untreated<br class=br>extensive small-<br class=br>cell lung cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1138 class=n-a></a>Chemotherapy alone<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1145 class=n-a></a>147</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1148 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1151 class=n-a></a>5.5: 5.3 months<br class=br>HR = 1.1<br class=br>95% CI 0.7–1.7<br class=br>unadjusted <i>p</i> = 0.82</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1163 class=n-a></a>13.3: 11.1 months<br class=br>HR = 0.8<br class=br>95% CI 0.5–1.3<br class=br>unadjusted <i>p</i> = 0.35</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1176 class=n-a></a>II–III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1179 class=n-a></a>Adding bevacizumab to<br class=br>chemotherapy does not<br class=br>improve PFS or OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1186 class=n-a></a><a href="#ref-36">36</a></td></tr><tr><a name=d12245e1190 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1191 class=n-a></a>Metastatic<br class=br>colorectal<br class=br>cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1198 class=n-a></a>Bevacizumab versus bevacizumab<br class=br>plus erlotinib</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1203 class=n-a></a>700</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1206 class=n-a></a>VEGF,<br class=br>VEGFR</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1211 class=n-a></a>4.9: 5.4 months<br class=br>stratified HR = 0.81<br class=br>95% CI 0.66–1.01<br class=br><i>p</i> = 0.059<br class=br>unstratified HR = 0.78<br class=br>95% CI 0.68–0.96<br class=br><i>p</i> = 0.019</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1231 class=n-a></a>24.9: 22.1 months<br class=br>stratified HR = 0.79<br class=br>95% CI 0.63–0.99<br class=br><i>p</i> = 0.036<br class=br>unstratified HR = 0.79<br class=br>95% CI 0.64–0.98<br class=br><i>p</i> = 0.035</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1252 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1255 class=n-a></a>Maintenance therapy<br class=br>with erlotinib plus<br class=br>bevacizumab shows<br class=br>signs of greater activity<br class=br>than bevacizumab alone</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1266 class=n-a></a><a href="#ref-37">37</a></td></tr><tr><a name=d12245e1270 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1271 class=n-a></a>Metastatic<br class=br>colorectal<br class=br>carcinoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1278 class=n-a></a>Ramucirumab versus<br class=br>placebo</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1283 class=n-a></a>1,072</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1286 class=n-a></a>VEGFR2</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1289 class=n-a></a>5.7: 4.5 months<br class=br>HR = 0.793<br class=br>95% CI 0.70–0.90<br class=br><i>p</i> = 0.0005</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1300 class=n-a></a>13.3: 11.7 months<br class=br>HR = 0.844<br class=br>95% CI 0.73–0.98<br class=br><i>p</i> = 0.0219</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1312 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1315 class=n-a></a>Adding ramucirumab<br class=br>to FOLFIRI significantly<br class=br>improves PFS and OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1322 class=n-a></a><a href="#ref-38">38</a></td></tr><tr><a name=d12245e1326 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1327 class=n-a></a>Advanced<br class=br>breast cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1332 class=n-a></a>Letrozole or fulvestrant alone<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1339 class=n-a></a>374</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1342 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1345 class=n-a></a>14.4: 19.3 months<br class=br>HR = 0.83<br class=br>95% CI 0.65–1.06<br class=br><i>p</i> = 0.126</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1356 class=n-a></a>51.8: 52.1 months<br class=br>HR = 0.87<br class=br>95% CI 0.58–1.32<br class=br><i>p</i> = 0.518</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1368 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1371 class=n-a></a>Adding bevacizumab to<br class=br>gemcitabine-docetaxel<br class=br>fails to improve PFS or OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1378 class=n-a></a><a href="#ref-39">39</a></td></tr><tr><a name=d12245e1383 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1384 class=n-a></a>Glioblastoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1387 class=n-a></a>Bevacizumab and temozolomide<br class=br>versus temozolomide alone</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1392 class=n-a></a>93</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1395 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1398 class=n-a></a>4.8: 2.2 months;<br class=br>HR = 0.70,<br class=br>95% CI 0.46–1.07<br class=br><i>p</i> = 0.10</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1409 class=n-a></a>10.6: 7.7 months<br class=br>HR = 0.68<br class=br>95% CI 0.44–1.04<br class=br><i>p</i> = 0.07</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1421 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1424 class=n-a></a>Adding bevacizumab to<br class=br>temozolomide is more<br class=br>active than temozolomide<br class=br>alone</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1433 class=n-a></a><a href="#ref-40">40</a></td></tr><tr><a name=d12245e1437 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1438 class=n-a></a>Non-metastatic<br class=br>renal cell<br class=br>carcinoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1445 class=n-a></a>Sunitinib or<br class=br>sorafenib<br class=br>versus<br class=br>placebo</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1454 class=n-a></a>1,323</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1457 class=n-a></a>VEGF,<br class=br>PDGFR,<br class=br>Ras-Raf-<br class=br>MAPK</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1466 class=n-a></a>(Sunitinib: placebo)<br class=br>70: 79.6 months<br class=br>HR = 1.02<br class=br>97.5% CI 0.85–1.23<br class=br><i>p</i> = 0.8038;<br class=br>(sorafenib: placebo)<br class=br>HR = 0.97<br class=br>97.5% CI 0.80–1.17<br class=br>Stratified log-rank<br class=br><i>p</i> = 0.7184</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1492 class=n-a></a>(Sunitinib: placebo)<br class=br>OS not reached<br class=br>HR = 1.17<br class=br>97.5% CI 0.90–1.52<br class=br><i>p</i> = 0.1762<br class=br>(sorafenib: placebo)<br class=br>HR = 0.98<br class=br>97.5% CI 0.75–1.28<br class=br>Stratified log-rank<br class=br><i>p</i> = 0.8577</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1519 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1522 class=n-a></a>Adjuvant treatment with<br class=br>sorafenib or sunitinib<br class=br>shows no survival benefit</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1529 class=n-a></a><a href="#ref-41">41</a></td></tr><tr><a name=d12245e1533 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1534 class=n-a></a>Metastatic renal<br class=br>cell carcinoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1539 class=n-a></a>Cabozantinib<br class=br>versus<br class=br>sunitinib</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1546 class=n-a></a>157</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1549 class=n-a></a>VEGFR2<br class=br>MET<br class=br>AXL</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1556 class=n-a></a>8.2: 5.6 months<br class=br>HR = 0.66<br class=br>95% CI 0.46–0.95<br class=br><i>p</i> = 0.012</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1567 class=n-a></a>30.3: 21.8 months<br class=br>HR = 0.80<br class=br>95% CI 0.50–1.26<br class=br><i>p</i> value not provided</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1579 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1582 class=n-a></a>Cabozantinib<br class=br>demonstrated a better<br class=br>clinical benefit than<br class=br>sunitinib</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1591 class=n-a></a><a href="#ref-42">42</a></td></tr><tr><a name=d12245e1595 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1596 class=n-a></a>Advanced renal<br class=br>cell carcinoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1601 class=n-a></a>Cabozantinib<br class=br>versus<br class=br>everolimus</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1608 class=n-a></a>658</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1611 class=n-a></a>VEGFR2<br class=br>MET<br class=br>AXL<br class=br>mTOR</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1620 class=n-a></a>7.4: 3.9 months<br class=br>HR = 0.51<br class=br>95% CI 0.41–0.62<br class=br><i>p</i> &lt;0.0001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1631 class=n-a></a>21.4: 16.5 months<br class=br>HR = 0.66<br class=br>95% CI 0.53–0.83<br class=br><i>p</i> = 0.00026</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1643 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1646 class=n-a></a>Cabozantinib increases<br class=br>PFS, OS, and objective<br class=br>response compared with<br class=br>everolimus</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1655 class=n-a></a><a href="#ref-43">43</a></td></tr><tr><a name=d12245e1659 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1660 class=n-a></a>Metastatic<br class=br>melanoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1665 class=n-a></a>Cabozantinib<br class=br>versus<br class=br>placebo</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1672 class=n-a></a>77</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1675 class=n-a></a>VEGFR2<br class=br>MET<br class=br>AXL</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1682 class=n-a></a>4.1: 2.8 months<br class=br>HR = 0.59<br class=br>95% CI Not reached<br class=br><i>p</i> = 0.284</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1693 class=n-a></a>Not provided</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1697 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1700 class=n-a></a>Cabozantinib has clinical<br class=br>anti-tumor activity but<br class=br>needs further clinical<br class=br>investigation</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1709 class=n-a></a><a href="#ref-44">44</a></td></tr><tr><a name=d12245e1713 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1714 class=n-a></a>Pleural<br class=br>mesothelioma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1719 class=n-a></a>Pemetrexed plus cisplatin with or<br class=br>without bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1724 class=n-a></a>448</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1727 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1730 class=n-a></a>9.2: 7.3 months<br class=br>HR = 0.61<br class=br>95% CI 0.50–0.75<br class=br><i>p</i> &lt;0.0001</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1741 class=n-a></a>18.8: 16.1 months<br class=br>HR = 0.77<br class=br>95% CI 0.62–0.95<br class=br><i>p</i> = 0.0167</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1753 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1756 class=n-a></a>Adding bevacizumab to<br class=br>pemetrexed plus cisplatin<br class=br>significantly improves PFS<br class=br>and OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1765 class=n-a></a><a href="#ref-45">45</a></td></tr><tr><a name=d12245e1770 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1771 class=n-a></a>Metastatic<br class=br>uterine<br class=br>leiomyosarcoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1778 class=n-a></a>Gemcitabine-docetaxel plus<br class=br>placebo<br class=br>versus<br class=br>plus bevacizumab</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1787 class=n-a></a>107</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1790 class=n-a></a>VEGF</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1793 class=n-a></a>6.2: 4.2 months<br class=br>HR = 1.12<br class=br>95% CI 0.74–1.7<br class=br><i>p</i> = 0.58</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1804 class=n-a></a>26.9: 23.3 months<br class=br>HR = 1.07<br class=br>95% CI 0.63–1.81<br class=br><i>p</i> = 0.81</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1816 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1819 class=n-a></a>Adding bevacizumab to<br class=br>gemcitabine-docetaxel<br class=br>fails to improve PFS or OS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1826 class=n-a></a><a href="#ref-46">46</a></td></tr><tr><a name=d12245e1830 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12245e1831 class=n-a></a>Metastatic soft<br class=br>tissue sarcoma</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1836 class=n-a></a>Pazopanib<br class=br>versus<br class=br>placebo</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1843 class=n-a></a>47</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1846 class=n-a></a>c-KIT,<br class=br>FGFR,<br class=br>PDGFR,<br class=br>VEGFR</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1855 class=n-a></a>24.7: 7.0 weeks<br class=br>HR = 0.41<br class=br>95% CI 0.19–0.90<br class=br><i>p</i> = 0.002</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1866 class=n-a></a>15.4: 14.9 months<br class=br>HR = 0.87<br class=br>95% CI 0.41–1.83<br class=br><i>p</i> = 0.687</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1878 class=n-a></a>III</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1881 class=n-a></a>Pazopanib significantly<br class=br>improves PFS</td><td colspan=1 rowspan=1 valign=top><a name=d12245e1886 class=n-a></a><a href="#ref-47">47</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d12245e1894 class=n-a></a><p id=d12245e1895> Ang, angiopoietin; CI, confidence interval; FGFR, fibroblast growth factor receptor; FOLFIRI, folinic acid, fluorouracil, and irinotecan; HR, hazard ratio; OS, overall survival; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor receptor; PFS, progression-free survival; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.</p></div></div></div><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12716/b93ff0d4-14ad-4d65-b64b-a627ab7546ca_figure1.gif"><img alt="b93ff0d4-14ad-4d65-b64b-a627ab7546ca_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12716/b93ff0d4-14ad-4d65-b64b-a627ab7546ca_figure1.gif"></a><div class=caption><h3>Figure 1. Schematic illustration of the role of the tumor microenvironment in resistance to anti-angiogenic therapy.</h3><p id=d12245e1910>Anti-angiogenic therapy inhibits tumor growth by reducing vessel density; however, the subsequent hypoxia and the responsive genes can cause resistance to such therapy. The hypoxia-related metabolic symbiosis, invasion and metastasis, vessel co-option, and vasculogenic mimicry (VM) lead to resistance to anti-angiogenic therapy. The recruitment of stromal cells also plays a critical role in resistance to anti-angiogenic therapy. Ang1/2, angiopoietin 1/2; CXCR4, C-X-C chemokine receptor type 4; EMT, epithelial-to-mesenchymal transition; EphA2, Eph receptor A2; FAK, focal adhesion kinase; FGF, fibroblast growth factor; GLUT1, glucose transporter-1; HGF, hepatocyte growth factor; HIF-1α, hypoxia-inducible factor 1α; IGF, insulin-like growth factor; LIAS, lipoic acid synthase; MCT4, monocarboxylate transporter 4; MDSC, myeloid-derived suppressor cell; MIF, macrophage migration inhibitory factor; mTOR, mammalian target of rapamycin; mtROS, mitochondria reactive oxygen species; OGDH, oxoglutarate dehydrogenase; PDGF, platelet-derived growth factor; PECAM, platelet endothelial cell adhesion molecule; SDF1, stromal cell-derived factor 1; TEM; Ties-expressing macrophage; Treg, regulatory T cell; VE-cadherin, vascular endothelial cadherin; VEGF, vascular endothelial growth factor.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12245e1920>The role of hypoxia in resistance to anti-angiogenic therapy</h2><p class="" id=d12245e1923>Previous studies have shown that resistance to anti-angiogenic therapy is associated with hypoxia-induced alterations, VEGF-independent cytokine-driven endothelial growth, mobilization of bone marrow-derived pro-angiogenic hematopoietic cells or endothelial progenitors, and vessel co-option<sup><a href="#ref-2">2</a>–<a href="#ref-5">5</a>,<a href="#ref-7">7</a></sup>. Anti-angiogenic therapy inhibits tumor growth effectively by reducing vessel density; however, the subsequent expression of hypoxia-inducible factors (HIFs) and the responsive genes (for example, <i>VEGF</i>, <i>VEGFR</i>, <i>carbonic anhydrase</i> [<i>CA</i>] <i>IX</i>, and <i>CAXII</i>) can lead to therapeutic resistance<sup><a href="#ref-8">8</a></sup>. In recent years, there has been growing evidence that hypoxia-triggered overexpression of HIF subunits and the activated downstream pathways play a critical role in resistance to anti-angiogenic therapy.</p><div class=section><a name=d12245e1959 class=n-a></a><h3 class=section-title>Role of HIF-1α in anti-angiogenic therapy</h3><p class="" id=d12245e1964>There are three α subunits (HIF-1α, -2α, and -3α) and one β subunit in the HIF family. HIF-1α is the oxygen-regulated subunit that has been studied in inflammation, diabetes, cardiovascular disease, and cancer. In the presence of O<sub>2</sub>, prolyl hydroxylase domain (PHD) proteins (principally PHD2) can use O<sub>2</sub> and a-ketoglutarate to subject HIF-1α to prolyl hydroxylation on proline residue 402/564<sup><a href="#ref-9">9</a></sup>. Von Hippel–Lindau protein recruits ubiquitin ligase complex by interacting with Elogin C after HIF-1α prolyl hydroxylation. Then, ubiquitinated HIF-1α can be recognized and degraded by the proteasome. Meanwhile, factor inhibiting 1 (FIH-1), which is an asparaginyl hydroxylase, can block HIF-1α transcription by blocking the interaction of HIF-1α transactivation domain with its co-activators p300 and CBP<sup><a href="#ref-9">9</a></sup>. When O<sub>2</sub> is deprived, the inhibition of prolyl hydroxylase (for example, PHD2) and asparaginyl hydroxylase activity (for example, FIH-1) increases the stability and transcription of HIF-1α and consequently causes the dimerization of HIF-1α and HIF-1β to form HIF1. HIF1 can bind to target genes and increase gene transcription<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d12245e1989>HIF-1α is a potent pro-angiogenic factor that has been associated with the regulation of VEGF, stromal cell-derived factor 1 (SDF1), plasminogen activator inhibitor 1 (PAI1), angiopoietins (Ang-1 and -2), platelet-derived growth factor (PDGF), Tie2 receptor, and matrix metalloproteinases (MMP-2 and -9)<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. The expression of HIF-1α is driven by hypoxia and mediated by histone deacetylase (HDAC). Deacetylation by HDAC is a critical post-translational modification to HIF-1α signaling. Upregulation of HDACs has been observed in response to increasing HIF-1α signaling under hypoxia<sup><a href="#ref-12">12</a></sup>. A phase I clinical trial showed that the addition of HDAC inhibitor abexinostat to pazopanib led to a durable response in some patients who experienced progression during anti-VEGF therapy<sup><a href="#ref-13">13</a></sup>. In addition, inhibiting HDACs can abrogate the expression of HIF-1α protein in hypoxic conditions and there is an additive or synergistic effect between HDAC and VEGFR inhibitors in resistant cancers<sup><a href="#ref-12">12</a>,<a href="#ref-14">14</a></sup>. <i>In vitro</i> and <i>in vivo</i> data have demonstrated that nucleus accumbens-associated protein-1 (NAC1), a critical molecule in promoting glycolysis under hypoxia, mediates glycolysis via HDAC4-mediated stabilization of HIF-1α. The knockdown of NAC1 exhibits anti-tumor effects of bevacizumab, which means that NAC1 may be involved in resistance to anti-angiogenic therapy<sup><a href="#ref-15">15</a></sup>. Thus, NAC1-HDAC4-HIF-1α signaling might be an important pathway in regulating resistance under hypoxia.</p></div><div class=section><a name=d12245e2026 class=n-a></a><h3 class=section-title>MET signaling</h3><p class="" id=d12245e2031>HIF-1α can also regulate the c-MET/HGF pathway, which can induce tumor angiogenesis through stimulation of endothelial cell (EC) proliferation, migration, and tubulogenesis<sup><a href="#ref-16">16</a></sup>. Hypoxia enhances c-MET/HGF signaling by activating HIF-1α in several types of cancers such as lung, ovarian, and cervical cancers<sup><a href="#ref-17">17</a></sup>. MET and VEGFR pathways share common downstream molecules such as mitogen-activated protein kinase (MAPK), ERK, AKT, and focal adhesion kinase (FAK), and the activation of c-MET/HGF might lead to the activation of VEGFR signaling. It has been shown that MET enhances the expression of VEGFA by interacting with src homology 2 domain containing and suppressing angiogenesis suppressor thrombospondin1<sup><a href="#ref-18">18</a></sup>. Other studies have also demonstrated that MET contributes to resistance to VEGF(R) inhibitors via the activation of ERK–MAPK and PI3K–AKT signaling<sup><a href="#ref-19">19</a></sup>. To identify mediators of resistance to anti-angiogenic therapy, Jahangiri <i>et al</i>.<sup><a href="#ref-20">20</a></sup> generated a novel glioma cell-derived bevacizumab-resistant xenograft model by injecting cells subcutaneously and harvesting the least responsive xenograft tumor cells and implanting them into mice with long-term treatment of bevacizumab (10 mg/kg). After the tumors were serially passaged subcutaneously (three cycles) <i>in vivo</i>, a stably resistant xenograft model was developed<sup><a href="#ref-20">20</a></sup>. Microarray analysis of this model showed upregulation of c-Met; adding a MET inhibitor with bevacizumab treatment impeded tumor invasion and prolonged survival in resistant mice<sup><a href="#ref-20">20</a></sup>. Cabozantinib, a multi-targeting inhibitor of MET, VEGFR2, AXL, and RET, can overcome HGF/MET signaling-mediated resistance to pan-VEGFR inhibition in neuroblastoma mouse models<sup><a href="#ref-21">21</a></sup>. Furthermore, c-MET can form a complex with β1-integrin extensively in bevacizumab-resistant GBM and result in increased migration<sup><a href="#ref-48">48</a></sup>. It has been demonstrated in some preclinical studies that increased invasiveness and metastasis is caused by c-MET activation due to the inhibition of VEGF signaling, which also results in resistance to anti-angiogenic therapy.</p><p class="" id=d12245e2077>c-MET/HGF signaling leads to the activation of numerous signaling cascades, especially those related to epithelial-to-mesenchymal transition (EMT). Anti-angiogenic treatment can activate the EMT repressor ZEB2 by upregulating HIF-1α. ZEB2 can downregulate ephrinB2 through promoter binding to enhance tumor invasiveness<sup><a href="#ref-49">49</a></sup>. The development of EMT has been confirmed in a multi-generational glioblastoma xenograft model, which is established by selecting the fastest growing tumor during bevacizumab treatment in each generation and reimplanting them into new mice. The authors observed that critical EMT transcription factors SNAI2 and ZEB2 were upregulated during bevacizumab treatment<sup><a href="#ref-50">50</a></sup>. A recent study showed a synergistic effect of c-MET and VEGFR inhibitor (sunitinib) in reducing invasiveness and metastasis of RIP-Tag2 and Panc-1 tumors<sup><a href="#ref-51">51</a></sup>. Similarly, another study demonstrated that VEGF could directly and negatively regulate GBM invasion by inhibiting MET activation, which is dependent on VEGFR2<sup><a href="#ref-52">52</a></sup>. Consequently, the broad use of anti-angiogenic therapy could restore and increase MET levels and induce EMT, which is confirmed in GBM patients who are resistant to bevacizumab<sup><a href="#ref-52">52</a></sup>. Overall, these data suggest that HGF/MET signaling plays a crucial role in increased invasiveness, metastasis, and drug resistance during anti-angiogenic therapy. The phase III METEOR trial demonstrated that cabozantinib (MET, VEGFR, and AXL inhibitor) treatment resulted in improvements in PFS, OS, and objective response rate in patients with advanced renal cell cancer and bone metastases after previous VEGFR inhibition therapy<sup><a href="#ref-53">53</a></sup>. Similarly, a phase II study showed that the dual MET/VEGFR2 inhibitor foretinib had anti-tumor activity in patients with papillary renal carcinoma and a high response rate in patients with germline <i>MET</i> mutations<sup><a href="#ref-54">54</a></sup>. These studies suggest a promising future for combining MET and VEGF/R inhibitors to overcome drug resistance.</p></div><div class=section><a name=d12245e2113 class=n-a></a><h3 class=section-title>Vascular mimicry</h3><p class="" id=d12245e2118>Tumor cells have a complex vasculature system that can develop compensatory mechanisms to evade therapeutic effect, such as revascularization. Vasculogenic mimicry (VM) is a blood supply system whereby vascular-like channels may form independently of ECs<sup><a href="#ref-55">55</a></sup>. VM is regulated by various molecules, including vascular endothelial cadherin (VE-cadherin), ephrin type-A receptor 2 (EphA2), platelet EC adhesion molecule (PECAM), VEGF, and FAK<sup><a href="#ref-56">56</a></sup>. In addition, hypoxia-related pathways, especially HIF-1α, are important regulatory mechanisms in the process of VM<sup><a href="#ref-57">57</a></sup>. Growing evidence indicates that tumor cells are capable of mimicking EC characteristics to form VM. It is reported that the VEGFR2 inhibitor sunitinib can increase VM under hypoxia by transforming tumor cells into endothelial-like cells<sup><a href="#ref-58">58</a></sup>. Another study showed that PECAM1 (also known as CD31, a mediator of angiogenesis that regulates EC–cell interactions) positive melanoma cells have the ability to form tube-like structures <i>in vitro</i> and could incorporate with vascular lumens <i>in vivo</i><sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. It was also confirmed that PECAM1<sup>+</sup> melanoma cells are enriched and might lead to resistance during anti-VEGF therapy<sup><a href="#ref-60">60</a></sup>. Similarly, in a breast cancer mouse model, VM channels were increased after treatment with sunitinib and related to increased hypoxia. However, this vessel regrowth exists only in the models bearing cells with the ability to form VM<sup><a href="#ref-61">61</a></sup>. Those findings showed that the process of VM depends mainly on specific tumor cell characteristics that can resemble EC features. Anti-angiogenic therapy-induced VM is highly related to hypoxia and leads to angiogenic rebound by forming endothelium-independent vascular channels.</p></div><div class=section><a name=d12245e2163 class=n-a></a><h3 class=section-title>Blood vessel co-option</h3><p class="" id=d12245e2168>In addition to VM, cancer cells can develop another vascular network for the resupply of oxygen and nutrients to escape anti-angiogenic therapy by blood vessel co-option<sup><a href="#ref-62">62</a></sup>. Vessel co-option is a process whereby cancer cells “hijack” pre-existing vasculature and migrate along the vessels of host organs to gain a blood supply<sup><a href="#ref-63">63</a></sup>. It has been shown that vessel co-option occurs mainly in well-vascularized organs such as the brain, lungs, and liver in both human cancers and animal models of cancer<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. A more recent study revealed that vessel co-option also occurs in lymph node metastases where it supports the growth of lymph node metastatic lesions. Furthermore, clinical evidence suggests that anti-angiogenic therapy (for example, bevacizumab) may not reduce vessel density in lymph node metastases from patients who received bevacizumab treatment<sup><a href="#ref-65">65</a></sup>. Other studies in preclinical models of glioblastoma and melanoma brain metastases have shown that tumor progression during treatment with anti-angiogenic drugs is associated with the induction of vessel co-option, which results in therapy resistance<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. In human lung metastases from breast, colorectal, or renal cancer, vessel co-option appears to be common, and in preclinical models of lung metastasis, vessel co-option was shown to be associated with resistance to sunitinib. The predominant mechanism of vessel co-option in metastatic tumors in the lungs is a process whereby cancer cells invade alveolar spaces and co-opt alveolar walls and their constituent alveolar capillaries. Subsequently, pneumocytes are lost from these co-opted alveolar walls, leaving behind the co-opted alveolar capillaries<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. Another preclinical study revealed that the VEGFR inhibitor sorafenib induces vessel co-option in an orthotopic model of hepatocellular carcinoma (HCC) and that this increase in vessel co-option was associated with resistance to sorafenib<sup><a href="#ref-70">70</a></sup>. Several pro-EMT transcription factors (for example, vimentin, ZEB1, and ZEB2) were upregulated significantly in the sorafenib-resistant tumors, which suggested a link between EMT and vessel co-option<sup><a href="#ref-70">70</a></sup>. Also, CD34<sup>+</sup> microvessels and α-smooth muscle actin (αSMA)<sup>+</sup> pericytes were depleted in both sorafenib-sensitive and -resistant tumor tissues compared with tissues without treatment, which indicates that the acquired resistance was not induced by the re-induction of angiogenesis<sup><a href="#ref-70">70</a></sup>. Importantly, other studies have also demonstrated that anti-angiogenic therapy can promote cancer cell invasion and induce an EMT switch, which is linked to acquired resistance<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. However, the molecular pathways involved in the induction of vessel co-option during anti-angiogenic therapy remain unclear. In addition, one study has shown that mCRC with histopathological features of co-opted vessels is associated with worse response to bevacizumab than patients with angiogenic metastases<sup><a href="#ref-73">73</a></sup>. However, further studies using patient samples obtained after treatment with anti-angiogenic therapy are needed to fully clarify the clinical association between vessel co-option and resistance to anti-angiogenic therapy.</p></div><div class=section><a name=d12245e2236 class=n-a></a><h3 class=section-title>Metabolic symbiosis</h3><p class="" id=d12245e2241>Another compensatory mechanism to hypoxia is metabolic symbiosis, a process in which tumor cells in the oxygenated region can use lactate from hypoxic, glycolytic tumor cells to produce ATP<sup><a href="#ref-74">74</a></sup>. This metabolic shift is driven by HIF-1α and is associated with the activation of glycolytic genes<sup><a href="#ref-75">75</a></sup>. Pisarsky <i>et al</i>.<sup><a href="#ref-76">76</a></sup> established a mouse orthotopic model with a stable murine breast cancer cell line (Py2T) and developed an evasive resistance model with long-term treatment with nintedanib (potent inhibitor of fibroblast growth factor [FGF] receptor 1 [FGFR1], 2, and 3, PDGF receptor α/β, and VEGFR1, 2, and 3). In this model, evasive resistance was found to be associated with the establishment of metabolic symbiosis but not tumor revascularization<sup><a href="#ref-74">74</a>,<a href="#ref-76">76</a></sup>. Allen <i>et al</i>. observed similar metabolic symbiosis with anti-angiogenic therapy in the RIP1-Tag2 transgenic mouse pancreatic neuroendocrine tumor (PanNET) model<sup><a href="#ref-77">77</a></sup>. Upregulation of glucose transporter 1 (GLUT1) and monocarboxylate transporter 4 (MCT4) in the hypoxic regions can be abrogated by knocking out HIF-1α<sup><a href="#ref-77">77</a></sup>. Furthermore, the mammalian target of rapamycin (mTOR) signaling pathway is involved in metabolic symbiosis during anti-angiogenic therapy, and the addition of rapamycin, an inhibitor of mTOR, can block this metabolism shift<sup><a href="#ref-77">77</a></sup>. Another study in a renal cell carcinoma patient-derived xenograft model showed that the metabolic symbiosis phenotype is involved in anti-angiogenic resistance and can be halted by blocking mTOR signaling<sup><a href="#ref-78">78</a></sup>. Inhibition of the upstream AKT/mTOR pathway can also sensitize renal cancer cells to multi-kinase inhibitor regorafenib<sup><a href="#ref-79">79</a></sup>.</p><p class="" id=d12245e2290>Mitochondria contribute to the major part of oxygen consumption and have been found to influence cell signaling by producing reactive oxygen species (ROS) and metabolites<sup><a href="#ref-80">80</a></sup>. Tie-2 receptors and one of the ligands, Ang-1, are related to the activation of ROS and angiogenic response. Mitochondrial ROS can be triggered by Ang1/Tie2 signaling, and the released ROS can mediate the Ang1/Tie2 pathway and pro-angiogenic response<sup><a href="#ref-81">81</a></sup>. In breast and lung cancer models, a multi-kinase inhibitor could induce hypoxia-mediated tumor glycolysis and switch it to long-term reliance on mitochondrial respiration<sup><a href="#ref-82">82</a></sup>. Mutation in two mitochondrial genes—oxoglutarate dehydrogenase (<i>OGDH</i>) and lipoic acid synthase (<i>LIAS</i>)—can stabilize HIF-1α in a non-hydroxylated form, and the depletion of OGDH or LIAS leads to increased HIF-1α<sup><a href="#ref-83">83</a></sup>. The induction of metabolic symbiosis in response to anti-angiogenic therapy enables tumor cells to circumvent the anti-tumor effects of therapeutic agents by using cell survival pathways. It is clear that mitochondria, as the primary energy factory, are highly involved in hypoxia responses and help tumor cells survive anti-angiogenic therapy.</p></div><div class=section><a name=d12245e2317 class=n-a></a><h3 class=section-title>Invasion and metastasis</h3><p class="" id=d12245e2322>Many studies have shown that anti-angiogenic therapy promotes tumor invasion and metastasis, which might be triggered by an anti-angiogenic therapy-associated increase in tumor hypoxia<sup><a href="#ref-49">49</a>,<a href="#ref-51">51</a>,<a href="#ref-52">52</a>,<a href="#ref-71">71</a>,<a href="#ref-84">84</a></sup>. The transcription of HIF-regulated genes is in control of diverse steps of tumor invasion and metastasis, including EMT, activation of MET signaling, recruitment of stromal cells, VM, and vessel co-option. It is reported that a triple-negative breast cancer mouse model exhibits increased MMP2 levels after discontinuation of sunitinib and VM channels were also observed accompanied by reduced endothelium-dependent vessel development<sup><a href="#ref-61">61</a></sup>. Data from patient samples revealed that the development of VM has a positive correlation with high expression of HIF-1α, MMP2, VE-cadherin, and CD31<sup><a href="#ref-61">61</a></sup>. In breast cancer, right open reading frame (RIO) kinase 3, a conserved protein of atypical serine/threonine protein kinases, is involved in promoting hypoxia-induced invasion and metastasis via maintaining actin cytoskeletal organization<sup><a href="#ref-85">85</a></sup>. Hypoxia induces circadian clock gene period 2 (<i>PER2</i>) degradation and enhances invasion and activation of EMT genes (<i>TWIST1</i>, <i>SLUG</i>, and <i>SNAIL</i>) in breast cancer<sup><a href="#ref-86">86</a></sup>. Two independent signaling loops have been clarified to be involved in hypoxia-stimulated breast cancer invasion and metastasis: (i) in C-X-C chemokine ligand 16 (CXCL16) signaling, cancer cells secrete CXCL16, which binds to C-X-C chemokine receptor type 6 (CXCR6) on mesenchymal stem cells (MSCs), and in turn MSCs secrete CXCL10, which binds to CXCR3 on cancer cells, and (ii) MSCs secrete chemokine ligand 5 (CCL5), which binds to C-C chemokine receptor type 5 (CCR5) on cancer cells, and cancer cells release colony-stimulating factor 1 (CSF1), which binds to CSF1R on MSCs<sup><a href="#ref-87">87</a></sup>. These two pathways are both dependent on HIF activity and promote the recruitment of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs)<sup><a href="#ref-87">87</a></sup>. Hence, hypoxia induced by anti-angiogenic therapy could promote tumor invasion by accelerating the development of VM, vessel co-option, and EMT phenotypes. As mentioned above, the HIF-1α–ZEB2–ephrinB2 axis is an important regulatory pathway in promoting tumor invasiveness and evasive resistance in glioma during bevacizumab treatment<sup><a href="#ref-49">49</a></sup>. Anti-angiogenic agents induced the accumulation of Tie2-expressing macrophages (TEMs) at the invasive front of glioma tumor and TEMs can enhance the invasiveness of glioma tumor by secreting MMPs<sup><a href="#ref-88">88</a></sup>. Altogether, these studies offer opportunities for overcoming invasion and metastasis resulting from anti-angiogenic therapy.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12245e2391>The role of stromal cells in resistance to anti-angiogenic therapy</h2><p class="" id=d12245e2394>TME is composed of resident (ECs and fibroblasts) and infiltrating (lymphocytes and macrophages) cells, extracellular matrix (collagen and fibronectin), and released molecules (cytokines, chemokines, antibodies, proteases, and angiogenic factors). One possible mechanism for resistance to anti-angiogenic therapy might be due to the recruitment of stromal cells. We and others have studied the complex interplay between ECs, platelets, pericytes, cancer-associated fibroblasts (CAFs), and white blood cells in the context of response to anti-angiogenic therapy<sup><a href="#ref-11">11</a>,<a href="#ref-89">89</a></sup>.</p><div class=section><a name=d12245e2404 class=n-a></a><h3 class=section-title>Endothelial cells</h3><p class="" id=d12245e2409>The crosstalk between ECs and other stromal cells plays a critical role in response to anti-angiogenic therapy. Ang/Tie signaling is one of the central pathways that controls blood vessel growth, cell–cell interactions, and anti-angiogenic resistance. Ang2-regulated interactions between ECs and pericytes/myeloid cells are among the resistance mechanisms to anti-angiogenic therapy. For instance, bevacizumab could enhance Ang2/Tie2 signaling in ECs and upregulate Ang2 expression, which leads to reduced pericyte coverage and increased macrophage infiltration in brain cancer<sup><a href="#ref-90">90</a></sup>. Heterogeneity of tumor ECs (TECs) might also contribute to resistance to anti-angiogenic therapy. TECs are different from normal ECs in many ways, including cell proliferation, migration, gene expression profile, and response to therapy. TECs are resistant to some chemotherapeutic drugs such as vincristine, 5-fluorouracil, and paclitaxel owing to the upregulation of drug resistance-associated genes<sup><a href="#ref-91">91</a></sup>. CXCR4 is selectively expressed in TECs, and CXCR4<sup>+</sup> TECs are related to poor outcome in patients with HCC. Functional studies revealed that CXCR4 is enriched in HCC angiogenic tip cells and overexpression of CXCR4 in ECs could stimulate vessel formation and sprouting <i>in vivo</i> and <i>in vitro</i>, implicating an important role for CXCR4<sup>+</sup> TECs in angiogenesis<sup><a href="#ref-92">92</a></sup>. Furthermore, sorafenib shows higher anti-tumor efficacy in HCC tumors with high CXCR4<sup>+</sup> expression<sup><a href="#ref-92">92</a></sup>. Interestingly, the recruitment of collagen type I<sup>+</sup>/CXCR4<sup>+</sup> fibrocyte-like cells can contribute to acquired resistance to bevacizumab<sup><a href="#ref-93">93</a></sup>. The activation of CXCR4, mediated mainly by CXCL12 (ligand for CXCR4), is induced by HIF-1α in hypoxic conditions<sup><a href="#ref-93">93</a></sup>. Similarly, a CXCR4 antagonist could interfere with neovascularization by preventing the interaction of CXCR4<sup>+</sup> bone marrow-derived myeloid cells (BMDCs) and SDF-1α<sup><a href="#ref-94">94</a></sup>. Collectively, these findings reveal potential markers for predicting response to anti-angiogenic therapy. Although the pathways by which TECs mediate resistance to anti-angiogenic therapy are not fully understood, such research holds promise for enhancing anti-angiogenic therapy.</p></div><div class=section><a name=d12245e2467 class=n-a></a><h3 class=section-title>Tumor-associated macrophages</h3><p class="" id=d12245e2472>BMDCs play a crucial role in the progression of angiogenesis and resistance to anti-angiogenic therapy. Many studies have shown that recruitment of BMDCs in GBM can cause resistance to vatalanib treatment and correspondingly the depletion of BMDCs can potentiate the effects of vatalanib<sup><a href="#ref-95">95</a>–<a href="#ref-97">97</a></sup>. Hypoxia-regulated neuropilin-1 (Nrp1), a marker of pro-angiogenic macrophages, can regulate the infiltration of TAMs into tumor hypoxic regions, and loss of Nrp1 in macrophages reduced angiogenesis and tumor growth<sup><a href="#ref-98">98</a></sup>. Future studies are needed to determine whether Nrp1 contributes to the acquisition of resistance to angiogenesis inhibitors and the underlying mechanisms. Another study revealed that the recruitment of TAMs in bevacizumab-resistant xenografts is caused by proliferation of differentiated macrophages and macrophage polarization and increases in numbers of pro-angiogenic macrophages<sup><a href="#ref-99">99</a></sup>. Bevacizumab can reduce macrophage inhibitory factor (MIF) expression at the edge of the tumor during early treatment while the loss of MIF leads to increased proliferation of TAMs in this area and eventual reprogramming into pro-angiogenic macrophages, even while treatment is continued<sup><a href="#ref-99">99</a></sup>. Pro-angiogenic macrophages promote tumor growth and invasion by secreting factors (for example, VEGFA, tumor necrosis factor alpha [TNFα], and interleukin-2 [IL-2]), eventually resulting in resistance to bevacizumab. In addition, hypoxia-induced chemokines (CXCL) and their receptors (CXCLR) have been shown to enhance the recruitment of TAMs and contribute to the emergence of therapeutic resistance<sup><a href="#ref-89">89</a></sup>.</p></div><div class=section><a name=d12245e2499 class=n-a></a><h3 class=section-title>Tie2-expressing macrophages</h3><p class="" id=d12245e2504>TEMs are a subpopulation of TAMs. Crosstalk between TEMs and other stromal cells can enhance pro-angiogenic effects. For example, the interaction of TEMs and Tie2<sup>+</sup> endothelial tip cells can promote vascular anastomoses during embryonic angiogenesis, and the blockade of the Ang2/Tie2 pathway in mannose receptor (MRC1)-expressing TEMs can impede angiogenesis<sup><a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>. In the RIP1-Tag2 pancreatic neuroendocrine tumor model, VEGFR2 inhibition upregulates Ang2 levels and enhances infiltration of TEMs. It can be halted by applying dual inhibitors of Ang2 and VEGFR2, which indicates that the adaptive enforcement of Ang2/Tie2 signaling induced by VEGFR inhibition may contribute to resistance<sup><a href="#ref-102">102</a></sup>. Similarly, in a murine GBM mouse model, blockade of Ang2 and VEGF resulted in decreased vascular permeability, decreased TEMs, and increased pericyte coverage and intratumoral T lymphocytes. Ang2 comes mainly from ECs and can mediate the interaction of ECs and myeloid cells<sup><a href="#ref-90">90</a></sup>. A strategy of dual blockade of Ang2 and VEGFR has shown better vascular normalization and TAM-phenotype shift than single-agent therapy<sup><a href="#ref-103">103</a></sup>. However, a recent phase II study showed that trebananib, an Ang1/2 inhibitor, was not effective as monotherapy in recurrent glioblastoma and did not improve outcomes in combination with bevacizumab. It is possible that such a dual inhibition strategy would be more effective in other cancer types<sup><a href="#ref-104">104</a></sup>.</p></div><div class=section><a name=d12245e2536 class=n-a></a><h3 class=section-title>Pericytes</h3><p class="" id=d12245e2541>Pericytes play an important role in angiogenesis and vessel maturation, although the specific mechanisms involved are only partially elucidated<sup><a href="#ref-105">105</a></sup>. Angiogenic sprouting of ECs is facilitated by the detachment of pericytes, and vessel maturation requires the recruitment of supporting pericytes. The interactions between pericytes and ECs mediated by Ang/Tie signaling are a crucial step for blood vessel stabilization<sup><a href="#ref-106">106</a>,<a href="#ref-107">107</a></sup>. A previous study demonstrated a bidirectional, reciprocal relationship between ECs and pericytes via Ang/Tie2 signaling, as pericytes can also express functional Tie2 receptor<sup><a href="#ref-108">108</a></sup>. Several studies have focused on elucidating the mechanisms of pericytes in vessel stabilization or dysfunction<sup><a href="#ref-106">106</a>,<a href="#ref-109">109</a>–<a href="#ref-111">111</a></sup>. In terms of whether targeting pericytes could alleviate resistance to anti-angiogenic therapy, there is variability in the preclinical data. Recruitment of pericytes to tumor blood vessels is mediated by PDGF signaling and dual targeting of VEGF-mediated angiogenesis, and PDGF-mediated pericyte recruitment was found to be more effective than targeting VEGF-mediated angiogenesis alone in a RIP1-Tag2 mouse model<sup><a href="#ref-112">112</a></sup>. However, a subsequent study demonstrated that the absence of pericytes in tumors does not enhance the efficacy of anti-VEGF therapy in pericyte-deficient <i>pdgfb<sup>ret/ret</sup> </i> mouse models<sup><a href="#ref-113">113</a></sup>.</p><p class="" id=d12245e2584>Several pericyte-targeted therapies (by targeting PDGFR, VEGFR, and Tie2) are aimed at reducing tumor angiogenesis by blocking EC–pericyte interactions<sup><a href="#ref-114">114</a></sup>. For example, trebananib (Ang2 inhibitor) and nintedanib (VEGFR/FGFR/PDGFR inhibitor) show clinical benefits for patients with advanced ovarian cancer when combined with chemotherapy (<a href="#T1">Table 1</a>). One study in patients with breast cancer has shown that an increased pericyte-covered microvascular density (MVD), a marker of vascular normalization, is associated with improved pathologic response during post-bevacizumab monotherapy<sup><a href="#ref-115">115</a></sup>. Some studies suggest that pericytes can be used for predicting response to anti-angiogenic therapy. A retrospective study has revealed that <i>PDGFR-β</i> which is related to pericyte maturation can predict bevacizumab efficacy in patients with colon cancer<sup><a href="#ref-116">116</a></sup>. Similarly, it was shown that, in triple-negative breast cancer, tumors with high PDGFRβ<sup>+</sup>/low desmin<sup>+</sup> pericytes coverage were more responsive to anti-angiogenic therapy<sup><a href="#ref-117">117</a></sup>. However, elucidating the mechanisms of pericytes mediating resistance to anti-angiogenic therapy still requires additional work.</p></div><div class=section><a name=d12245e2617 class=n-a></a><h3 class=section-title>Endothelial progenitor cells</h3><p class="" id=d12245e2622>Endothelial progenitor cells (EPCs) have been shown to promote the angiogenic switch in solid tumors, and the recruitment of EPCs from bone marrow can directly contribute to tumor development and colonization. The recruitment of EPCs is induced primarily by hypoxia, and their contribution to tumor vasculature might stimulate resistance to anti-VEGF therapies<sup><a href="#ref-89">89</a>,<a href="#ref-118">118</a></sup>. Various factors are involved in the activation and mobilization of EPCs, including HIF-1α, VEGF, SDF1, MMPs, and membrane-bound kit ligand (mbKitL)<sup><a href="#ref-89">89</a></sup>. A recent study showed that interactions between EPCs and ECs are independent of hypoxia and the pro-angiogenic effects of EPCs on ECs were not completely dependent on the presence of VEGFA<sup><a href="#ref-119">119</a></sup>. Thus, VEGF-independent activation of EPCs could counteract the effects of anti-VEGF therapy and result in resistance. The circulating EPC frequency and the level of phospho-ERK in EPCs are a potential biomarker of sorafenib efficacy<sup><a href="#ref-120">120</a></sup>.</p></div><div class=section><a name=d12245e2645 class=n-a></a><h3 class=section-title>Myeloid-derived suppressor cells</h3><p class="" id=d12245e2650>MDSCs can promote metastasis in animal models and cancer patients by supporting tumor cell survival, angiogenesis, invasion, and metastasis<sup><a href="#ref-121">121</a>,<a href="#ref-122">122</a></sup>. The role of immature myeloid cells/MDSCs in mediating resistance to anti-angiogenic therapy was first reported in preclinical studies by Shojaei <i>et al</i>.<sup><a href="#ref-123">123</a>,<a href="#ref-124">124</a></sup>. It has been suggested that MDSCs cause tumor resistance to anti-angiogenic therapy in several different ways, including (i) enhanced recruitment and infiltration of MDSCs, (ii) altered gene expression, (iii) phenotype differentiation, and (iv) activation of alternative growth factors<sup><a href="#ref-89">89</a>,<a href="#ref-125">125</a>–<a href="#ref-127">127</a></sup>. A persistence of intratumoral MDSCs is observed in sunitinib-resistant mouse models and may be related to local expression of granulocyte macrophage colony-stimulating factor (GM-CSF) and activation of STAT5<sup><a href="#ref-126">126</a></sup>. This is confirmed in patients with sunitinib-treated tumors that show persistent elevation in MDSCs with increasing levels of pro-angiogenic factors such as MMPs and IL-8<sup><a href="#ref-126">126</a></sup>. However, the detailed pathways of MDSC-mediated resistance to anti-angiogenic therapy and their clinical relevance are not fully understood.</p></div><div class=section><a name=d12245e2690 class=n-a></a><h3 class=section-title>Platelets</h3><p class="" id=d12245e2695>As a well-known mediator for thrombosis and hemostasis, platelets have been recognized as a critical component of angiogenesis, metastasis, and tumor progression via releasing pro-angiogenic and anti-angiogenic factors<sup><a href="#ref-128">128</a>,<a href="#ref-129">129</a></sup>. Although the functional role of platelets in regulating angiogenesis has been reviewed<sup><a href="#ref-130">130</a></sup>, little is known about the role of platelets in response to anti-angiogenic therapy. Platelets might mediate resistance to anti-angiogenic therapy by secreting various growth factors and cytokines, interaction with EPCs and pericytes, uptaking anti-VEGF drugs, and promoting tumor invasion and metastasis<sup><a href="#ref-89">89</a></sup>. Platelet contents such as PDGF, FGF, angiostatin, and insulin-like growth factor (IGF) contribute to the development of tumors by interacting with myeloid cells or stimulating angiogenic factors<sup><a href="#ref-131">131</a>,<a href="#ref-132">132</a></sup>. A recent study demonstrated that platelet releasate exhibits a powerful pro-angiogenic effect on GBM-derived ECs and contains a high level of VEGF in patients with GBM as compared with normal controls<sup><a href="#ref-133">133</a></sup>.</p></div><div class=section><a name=d12245e2725 class=n-a></a><h3 class=section-title>Other mechanisms</h3><p class="" id=d12245e2730>CAFs play a critical role in the TME. The expression of SDF1 and PDGF-C in CAFs has been reported in drug-resistant tumors<sup><a href="#ref-89">89</a></sup>. Crawford <i>et al</i>. first reported a role of CAFs in mediating resistance to anti-angiogenic therapy in a preclinical study<sup><a href="#ref-134">134</a></sup>. A recent study reported that CD44<sup>+</sup> CAFs are increased following treatment with angiogenesis inhibitors and contribute to the maintenance of cancer stem cell populations, which associate with drug resistance<sup><a href="#ref-135">135</a></sup>. Marrow-derived fibrocyte-like cells with expression of alpha-1 type I collagen and CXCR4 have been demonstrated to contribute to acquired resistance to bevacizumab by producing FGF2<sup><a href="#ref-93">93</a></sup>. Anti-angiogenic therapy has been shown to modulate and enhance the immune response in patients with cancer. For example, decreased regulatory T (Treg) cells have been noted during bevacizumab treatment in patients with mCRC and GBM<sup><a href="#ref-136">136</a></sup>. Recent studies found that bevacizumab could increase CD4<sup>+</sup> lymphopenia, which is associated with poor survival in GBM patients and immune response suppression<sup><a href="#ref-136">136</a></sup>. However, another study showed that bevacizumab did not change the number, proliferation, or activation status in T-cell subsets within tumors but rather increased the percentage of M1/pro-inflammatory-polarized anti-tumor TAMs<sup><a href="#ref-137">137</a></sup>. A similar study showed that bevacizumab did not increase circulating suppressive MDSCs (lineage–HLADR–CD11b<sup>+</sup>CD33<sup>+</sup>) but can increase the circulating concentration of soluble VEGFA<sup><a href="#ref-136">136</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12245e2786>Targeting tumor microenvironment to overcome therapeutic resistance</h2><p class="" id=d12245e2789>The compensatory mechanisms such as the expression of other pro-angiogenic factors, hypoxia, and the crosstalk between tumor and stromal cells can be a new target to overcome resistance to anti-angiogenesis therapy. The emerging strategies targeting TME include new specific inhibitors, combined pathway inhibitors, multi-targeting strategies, and new approaches for drug delivery.</p><div class=section><a name=d12245e2792 class=n-a></a><h3 class=section-title>New inhibitors</h3><p class="" id=d12245e2797>Several specific antagonists of VEGF(R) have been investigated in recent years. iVR1, a new inhibitor of VEGFR1, could inhibit colorectal cancer growth, macrophage migration, and monocyte mobilization by blocking the phosphorylation of VEGFR1<sup><a href="#ref-138">138</a></sup>. Meanwhile, new antibodies are being investigated to target different molecules except for VEGF. For example, monoclonal antibodies against endoglin (CD105), a protein receptor of the transforming growth factor-beta (TGF-β) superfamily, showed a promising anti-vascular effect<sup><a href="#ref-139">139</a></sup>. A single-chain fragment of anti-human Ang2 has been shown to inhibit tumor growth, reduce vascular permeability, and extend survival in a bevacizumab-treatment GBM mouse model<sup><a href="#ref-140">140</a></sup>. Delta-like ligand 4-NOTCH1 signaling has been demonstrated to mediate tumor resistance to anti-VEGF therapy in preclinical models by activating multiple pathways<sup><a href="#ref-141">141</a></sup>. In preclinical ovarian cancer models, we have shown that dual targeting of DLL4 and VEGF exhibits superior anti-tumor effects<sup><a href="#ref-142">142</a></sup>. Two humanized DLL4 antibodies—enoticumab (REGN421) and demcizumab (OMP-21M18)—have shown preliminary anti-tumor activity in ovarian cancer and other solid tumors in phase I studies<sup><a href="#ref-143">143</a>,<a href="#ref-144">144</a></sup>. A bispecific DLL4/VEGF (OMP-305B83) antibody is also in phase Ib investigation with paclitaxel in ovarian cancer (ClinicalTrials.gov identifier: NCT03030287).</p></div><div class=section><a name=d12245e2829 class=n-a></a><h3 class=section-title>Combined pathway inhibitors</h3><p class="" id=d12245e2834>As hypoxia plays a critical role in cancer progression, metastasis, and resistance to anti-angiogenic therapy, the development of hypoxia inhibitors could be a powerful approach for cancer treatment. A novel small molecule named saltern amide A (SA) can inhibit HIF-1α in various human cancer cells. SA suppressed PI3K/AKT/mTOR, p42/44 MAPK, and STAT3 signaling<sup><a href="#ref-145">145</a></sup>. Results from a phase I trial of bortezomib (a HIF-1α transcriptional activity suppressor) plus bevacizumab demonstrated clinical activity in patients with various tumors, including renal cell, breast, and ovarian/fallopian tube cancers<sup><a href="#ref-146">146</a></sup>. A phase I study in a combination with bevacizumab and EZN-2208 (PEGylated SN-38), another HIF-1α transcriptional activity inhibitor, showed acceptable toxicity in patients with refractory solid tumors. However, owing to the limited number of patients, the results did not demonstrate a conclusive effect of EZN-2208 on the activity of HIF-1α<sup><a href="#ref-147">147</a></sup>. The combination of an HDAC inhibitor and anti-angiogenic agents can downregulate HIF-1α and VEGF expression<sup><a href="#ref-13">13</a></sup>. Similarly, another study showed that the combination of metronomic topotecan and pazopanib can improve treatment response compared with the single drugs alone in metastatic triple-negative breast cancer<sup><a href="#ref-106">106</a></sup>. The potential mechanism might be related to the downregulation of HIF-1α induced by low-dose, continuous topotecan treatment<sup><a href="#ref-148">148</a></sup>. HIF-1α dimerization inhibitor acriflavine can enhance the anti-tumor efficacy of sunitinib by inhibiting VEGF and TGF-β expression and the accumulation of MDSCs in the spleen<sup><a href="#ref-149">149</a></sup>.</p><p class="" id=d12245e2866>Given the adaptation of the immune cells during anti-angiogenic therapy, combination of anti-angiogenic agents with immune drugs is being investigated. Immune checkpoint inhibitors such as ipilimumab, nivolumab, and pembrolizumab show promising anti-tumor effects by augmenting anti-tumor immune responses<sup><a href="#ref-150">150</a>,<a href="#ref-151">151</a></sup>. Programmed cell death-1 (PD-1) receptor, the negative immune checkpoint regulator, and its ligand, PD-L1, which can suppress immune response, have been shown to be upregulated during anti-angiogenic therapy<sup><a href="#ref-152">152</a>,<a href="#ref-153">153</a></sup>. Thus, it provides feasible approaches to enhance response to anti-angiogenic therapy by adding immune checkpoint inhibitors. Several studies have reported that adding immune checkpoint agents shows improved clinical benefit compared with anti-angiogenic monotherapy<sup><a href="#ref-154">154</a></sup>. A2V, a novel bevacizumab-based bispecific human IgG1 antibody that targets Ang2 and VEGFA, has been found to promote anti-tumor immunity by activating tumor-infiltrating CD8<sup>+</sup> T cells, increasing tumor antigen presentation, and enhancing perivascular T-cell accumulation<sup><a href="#ref-152">152</a></sup>. Also, A2V can increase PD-L1 expression via interferon-gamma (IFNγ) signaling and combining PD-1 blockade and A2V can improve the anti-tumor activity in certain tumor models<sup><a href="#ref-152">152</a></sup>. The enhanced effect of adding PD-L1 inhibitor to anti-angiogenic therapy is dependent on the induction of high endothelial venules, which can facilitate lymphocyte infiltration via lymphotoxin β receptor signaling<sup><a href="#ref-153">153</a></sup>. A series of clinical trials of combined anti-angiogenic therapy with immune checkpoint therapy is ongoing<sup><a href="#ref-154">154</a></sup>.</p><p class="" id=d12245e2907>As VEGF-independent angiogenesis pathways can contribute to resistance to anti-VEGF therapy, the combination treatment of chemotherapeutic agents and anti-VEGF therapy may overcome such drug resistance. A study of the combination of vascular disrupting agents (VDAs) and sunitinib was found to result in improved treatment efficacy in a colorectal liver metastasis mouse model by reducing tumor proliferation and vasculature and increasing tumor apoptosis<sup><a href="#ref-155">155</a></sup>. Similarly, a phase II trial showed that the addition of VDAs to bevacizumab can extend PFS duration in patients with recurrent ovarian cancer<sup><a href="#ref-30">30</a></sup>. The combination of VEGF/VEGFR inhibitors with anti-invasive drugs or vessel co-option inhibitors may provide another possibility to overcome resistance. A recent phase I study in patients with recurrent GBM tested the combined effect of the VEGFR inhibitor cediranib with the invasion inhibitor cilengitide. Although no increased toxicities were observed in the combination treatment of cediranib and cilengitide, no survival benefit was shown<sup><a href="#ref-156">156</a></sup>. However, recent preclinical work has shown that cilengitide can in fact promote tumor invasion, tumor growth, and tumor angiogenesis and therefore may not be the ideal drug to combine with anti-angiogenic therapy in the clinic<sup><a href="#ref-157">157</a>,<a href="#ref-158">158</a></sup>. Despite the promising future of combining anti-angiogenic therapy with anti-invasive agents or vessel co-option inhibitors, successful clinical translation has yet to be achieved.</p></div><div class=section><a name=d12245e2930 class=n-a></a><h3 class=section-title>Multi-targeting strategy</h3><p class="" id=d12245e2935>Based on the compensatory responses to anti-VEGF therapy, combining treatments that target multiple angiogenic signals could be important. Preclinical models showed that the combination of multi-tyrosine kinase inhibitors lenvatinib (VEGFR, FGFR, and RET inhibitor) and golvatinib (E7050; c-Met, Tie2, and EphB4 inhibitor) could inhibit the development of pericytes and infiltration of TEMs in thyroid and endometrial cancer models<sup><a href="#ref-159">159</a></sup>. Apart from VEGF/VEGFR inhibitors, targeting PDGF/PDGFR signaling can also improve the efficacy of current therapy and reduce tumor growth, invasion, and metastasis<sup><a href="#ref-160">160</a></sup>. Nonetheless, one study showed that the depletion of pericytes by imatinib and sunitinib not only can reduce tumor growth but also can increase metastasis and EMT progression<sup><a href="#ref-161">161</a></sup>. Another study revealed that depletion of PDGFRβ<sup>+</sup> pericytes at early stages of tumor progression reduced metastasis but enhanced metastasis at later stages; further study implicated Ang2 as a key mediator of the metastatic phenotype<sup><a href="#ref-162">162</a></sup>. Notably, the increased metastasis induced by pericyte depletion can be limited by additional MET or Ang2 inhibitors, which may provide a new and efficient strategy to suppress tumor growth while minimizing the risk of metastasis<sup><a href="#ref-161">161</a>,<a href="#ref-162">162</a></sup>. A heparin-derived angiogenesis inhibitor, LHT7, targeting FGF2 and PDGF-β, could inhibit the maturation of endothelium and can serve as a potential drug together with VEGF inhibitors to overcome resistance<sup><a href="#ref-163">163</a></sup>. Further study indicated that the combination of LHT7 and a selective cyclooxygenase-2 (COX2) inhibitor (celecoxib) showed a stronger therapeutic effect than anti-angiogenic drugs alone<sup><a href="#ref-164">164</a></sup>. COX2 has been reported to counteract the efficacy of anti-angiogenic agents<sup><a href="#ref-164">164</a></sup>. Lucitanib (a multi-target inhibitor of VEGFR1 to 3, PDGFRα/β, and FGFR1 to 3) has demonstrated activity in phase I/II clinical testing in patients with breast cancer<sup><a href="#ref-165">165</a></sup>. Another novel method to overcome resistance to bevacizumab therapy is combining VEGF inhibitors with pericyte-targeted drugs (mostly inhibitors of Ang or PDGFRβ). Ang2 and the VEGFA inhibitor A2V exert anti-tumor effects in a variety of ways, including impairing tumor angiogenesis, reducing metastasis, and increasing the infiltration of pro-inflammatory macrophages<sup><a href="#ref-137">137</a>,<a href="#ref-166">166</a></sup>. In a xenograft model of ovarian cancer, dual targeting of VEGF and Ang has been shown to result in greater inhibition of tumor angiogenesis and metastasis than monotherapy with either VEGF or Ang inhibitors<sup><a href="#ref-167">167</a></sup>. Another study showed that VEGF inhibitor and Ang2 inhibitor can potentially reduce resistance to anti-angiogenic therapy<sup><a href="#ref-90">90</a></sup>. Furthermore, imatinib could inhibit PDGFR<sup>+</sup> pericyte-like cells and disrupt tumor vascular integrity as well as EC survival<sup><a href="#ref-168">168</a></sup>. While trebananib (a first-in-class peptibody targeting Ang2) exhibited clinical benefit in patients with ovarian cancer, it was ineffective as monotherapy and did not enhance the effect of bevacizumab in patients with recurrent glioblastoma<sup><a href="#ref-104">104</a>,<a href="#ref-169">169</a></sup>. As first-line therapy, brivanib (a dual inhibitor of VEGFR and FGFR) had a similar anti-tumor effect but was less well tolerated compared with sorafenib in a phase III study<sup><a href="#ref-170">170</a></sup>. Another phase III study showed that brivanib as second-line therapy did not result in improved outcomes of HCC patients who did not respond to sorafenib<sup><a href="#ref-171">171</a></sup>. Additional work is needed to understand the true efficacy of multi-targeted therapy in different cancer types.</p></div><div class=section><a name=d12245e3022 class=n-a></a><h3 class=section-title>Drug delivery</h3><p class="" id=d12245e3027>Nanoparticles can be designed with specific target proteins to deliver drugs into target cells. New sorafenib-loaded CXCR4-targeted nanoparticles have been designed to treat HCC. The results of <i>in vitro</i> and <i>in vivo</i> studies show that it can reduce the infiltration of TAMs and enhance anti-angiogenic effects. Nanoparticles designed to deliver sorafenib into tumors efficiently could be an innovative approach to overcome drug resistance<sup><a href="#ref-172">172</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12245e3044>Conclusions</h2><p class="" id=d12245e3047>Although mechanistic links between TME and anti-angiogenic therapy have been studied, the overall mechanisms of resistance to anti-angiogenic therapy require additional work. The combination of VEGF(R) inhibitors and other pathway inhibitors, including hypoxia inhibitors or immune checkpoint inhibitors, is being evaluated in various clinical trials. Unfortunately, reliable biomarkers for predicting response or the emergence of resistance have not been identified. It is likely that combination treatments will be required for overcoming drug resistance and prolonging patient survival. In summary, anti-angiogenesis therapies remain a highly effective avenue for cancer therapy. Understanding the mechanisms of adaptive resistance will allow an improved understanding of the complex underlying biology and holds tremendous potential for innovative drug development.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12245e3054>Abbreviations</h2><p class="" id=d12245e3057>Ang, angiopoietin; BMDC, bone marrow-derived cell; CA, carbonic anhydrase; CAF, cancer-associated fibroblast; COX2, cyclooxygenase-2; CSF1, colony-stimulating factor 1; CXCL, C-X-C chemokine ligand; CXCR, C-X-C chemokine receptor; EC, endothelial cell; EMT, epithelial-to-mesenchymal transition; EPC, endothelial progenitor cell; FAK, focal adhesion kinase; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; FIH-1, factor inhibiting 1; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; HDAC, histone deacetylase; HIF, hypoxia-inducible factor; IL, interleukin; mCRC, metastatic colorectal cancer; MAPK, mitogen-activated protein kinase; MDSC, myeloid-derived suppressor cell; MIF, macrophage inhibitory factor; MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; mTOR, mammalian target of rapamycin; NAC1, nucleus accumbens-associated protein-1; Nrp1, neuropilin-1; OGDH, oxoglutarate dehydrogenase; OS, overall survival; PD-1, programmed cell death-1; PDGF, platelet-derived growth factor; PECAM, platelet endothelial cell adhesion molecule; PFS, progression-free survival; PHD, prolyl hydroxylase domain; ROS, reactive oxygen species; SA, saltern amide A; SDF1, stromal cell-derived factor 1; TAM, tumor-associated macrophage; TEC, tumor endothelial cell; TEM, Tie2-expressing macrophage; TGF-β, transforming growth factor-beta; TME, tumor microenvironment; VDA, vascular disrupting agent; VE-cadherin, vascular endothelial cadherin; VEGF/R, vascular endothelial growth factor/receptor; VM, vasculogenic mimicry</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d12245e1 class=n-a></a><h2 class=main-title id=d12789>Competing interests</h2><p class=metadata-entry><a name=d12245e178 class=n-a></a><p id=d12245e179> RLC has received grant funding from Genentech, Merck, Janssen, Clovis, AZ, and Abbvie and serves on the scientific steering committee as an investigator for Tesaro, Clovis, AZ, and Abbvie. AKS serves on the advisory board for Kiyatec and has received research funding from M-Trap. The other authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d12245e1 class=n-a></a><h2 class=main-title id=d12791>Grant information</h2><p>Portions of this work were supported by the National Institutes of Health (P50 CA217685, P50 CA098258, CA177909, and R35 CA209904), the Frank McGraw Memorial Chair in Cancer Research, the Ann Rife Cox Chair in Gynecology, the American Cancer Society Research Professor Award, and the Institutional Core Grant (CA16672) to the MD Anderson Cancer Center from the National Institutes of Health.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d12245e3064 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d13406>References</h2><div class="section ref-list"><a name=d12245e3064 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d12245e3071 class=n-a></a>Nandikolla AG, Rajdev L: Targeting angiogenesis in gastrointestinal tumors: current challenges. <i>Transl Gastroenterol Hepatol.</i> 2016; <b>1</b>: 67. <a target=xrefwindow id=d12245e3079 href="http://www.ncbi.nlm.nih.gov/pubmed/28138633">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3082 href="http://dx.doi.org/10.21037/tgh.2016.08.04">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3085 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5244743">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d12245e3094 class=n-a></a>Vasudev NS, Reynolds AR: Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. <i>Angiogenesis.</i> 2014; <b>17</b>(3): 471–94. <a target=xrefwindow id=d12245e3102 href="http://www.ncbi.nlm.nih.gov/pubmed/24482243">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3105 href="http://dx.doi.org/10.1007/s10456-014-9420-y">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3108 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4061466">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d12245e3117 class=n-a></a>Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. <i>Nat Rev Cancer.</i> 2008; <b>8</b>(8): 592–603. <a target=xrefwindow id=d12245e3125 href="http://www.ncbi.nlm.nih.gov/pubmed/18650835">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3128 href="http://dx.doi.org/10.1038/nrc2442">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3131 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2874834">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d12245e3140 class=n-a></a>Ebos JM, Kerbel RS: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. <i>Nat Rev Clin Oncol.</i> 2011; <b>8</b>(4): 210–21. <a target=xrefwindow id=d12245e3148 href="http://www.ncbi.nlm.nih.gov/pubmed/21364524">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3151 href="http://dx.doi.org/10.1038/nrclinonc.2011.21">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3154 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4540336">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d12245e3163 class=n-a></a>Sennino B, McDonald DM: Controlling escape from angiogenesis inhibitors. <i>Nat Rev Cancer.</i> 2012; <b>12</b>(10): 699–709. <a target=xrefwindow id=d12245e3171 href="http://www.ncbi.nlm.nih.gov/pubmed/23001349">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3174 href="http://dx.doi.org/10.1038/nrc3366">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3177 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3969886">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d12245e3187 class=n-a></a>Hartmann S, Bhola NE, Grandis JR: HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. <i>Clin Cancer Res.</i> 2016; <b>22</b>(16): 4005–13. <a target=xrefwindow id=d12245e3195 href="http://www.ncbi.nlm.nih.gov/pubmed/27370607">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3198 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-0951">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732792427"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3207 class=n-a></a>Torok S, Rezeli M, Kelemen O, <i> et al.</i>: Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. <i>Theranostics.</i> 2017; <b>7</b>(2): 400–412. <a target=xrefwindow id=d12245e3218 href="http://www.ncbi.nlm.nih.gov/pubmed/28042343">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3221 href="http://dx.doi.org/10.7150/thno.16767">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3225 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5197073">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732792427">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d12245e3238 class=n-a></a>Vaeteewoottacharn K, Kariya R, Dana P, <i> et al.</i>: Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma. <i>Tumour Biol.</i> 2016; <b>37</b>(7): 9023–35. <a target=xrefwindow id=d12245e3249 href="http://www.ncbi.nlm.nih.gov/pubmed/26762407">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3252 href="http://dx.doi.org/10.1007/s13277-016-4785-8">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d12245e3261 class=n-a></a>Semenza GL: Regulation of oxygen homeostasis by hypoxia-inducible factor 1. <i>Physiology (Bethesda).</i> 2009; <b>24</b>: 97–106. <a target=xrefwindow id=d12245e3269 href="http://www.ncbi.nlm.nih.gov/pubmed/19364912">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3272 href="http://dx.doi.org/10.1152/physiol.00045.2008">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d12245e3281 class=n-a></a>Muz B, de la Puente P, Azab F, <i> et al.</i>: The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. <i>Hypoxia (Auckl).</i> 2015; <b>3</b>: 83–92. <a target=xrefwindow id=d12245e3292 href="http://www.ncbi.nlm.nih.gov/pubmed/27774485">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3295 href="http://dx.doi.org/10.2147/HP.S93413">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5045092">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d12245e3308 class=n-a></a>Ulivi P, Marisi G, Passardi A: Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. <i>Oncotarget.</i> 2016; <b>7</b>(29): 46678–46691. <a target=xrefwindow id=d12245e3316 href="http://www.ncbi.nlm.nih.gov/pubmed/27081084">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3319 href="http://dx.doi.org/10.18632/oncotarget.8712">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3322 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5216829">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d12245e3332 class=n-a></a>Ellis L, Hammers H, Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors. <i>Cancer Lett.</i> 2009; <b>280</b>(2): 145–53. <a target=xrefwindow id=d12245e3340 href="http://www.ncbi.nlm.nih.gov/pubmed/19111391">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3343 href="http://dx.doi.org/10.1016/j.canlet.2008.11.012">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3346 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2814368">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727327694"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3355 class=n-a></a>Aggarwal R, Thomas S, Pawlowska N, <i> et al.</i>: Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. <i>J Clin Oncol.</i> 2017; <b>35</b>(11): 1231–1239. <a target=xrefwindow id=d12245e3366 href="http://www.ncbi.nlm.nih.gov/pubmed/28221861">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3369 href="http://dx.doi.org/10.1200/JCO.2016.70.5350">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3373 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5791833">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727327694">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d12245e3386 class=n-a></a>Tavallai S, Hamed HA, Grant S, <i> et al.</i>: Pazopanib and HDAC inhibitors interact to kill sarcoma cells. <i>Cancer Biol Ther.</i> 2014; <b>15</b>(5): 578–85. <a target=xrefwindow id=d12245e3397 href="http://www.ncbi.nlm.nih.gov/pubmed/24556916">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3400 href="http://dx.doi.org/10.4161/cbt.28163">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3404 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4026080">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727423383"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3413 class=n-a></a>Zhang Y, Ren YJ, Guo LC, <i> et al.</i>: Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1α axis. 2017. <a target=xrefwindow id=d12245e3418 href="http://www.ncbi.nlm.nih.gov/pubmed/28319066">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3421 href="http://dx.doi.org/10.1038/onc.2017.51">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3424 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5537617">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727423383">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d12245e3437 class=n-a></a>Abounader R, Laterra J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. <i>Neuro Oncol.</i> 2005; <b>7</b>(4): 436–51. <a target=xrefwindow id=d12245e3445 href="http://www.ncbi.nlm.nih.gov/pubmed/16212809">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3448 href="http://dx.doi.org/10.1215/S1152851705000050">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3451 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1871724">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1014316"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3460 class=n-a></a>Pennacchietti S, Michieli P, Galluzzo M, <i> et al.</i>: Hypoxia promotes invasive growth by transcriptional activation of the <i>met</i> protooncogene. <i>Cancer Cell.</i> 2003; <b>3</b>(4): 347–61. <a target=xrefwindow id=d12245e3474 href="http://www.ncbi.nlm.nih.gov/pubmed/12726861">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3478 href="http://dx.doi.org/10.1016/S1535-6108(03)00085-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1014316">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d12245e3492 class=n-a></a>Jeon HM, Lee J: MET: roles in epithelial-mesenchymal transition and cancer stemness. <i>Ann Transl Med.</i> 2017; <b>5</b>(1): 5. <a target=xrefwindow id=d12245e3500 href="http://www.ncbi.nlm.nih.gov/pubmed/28164090">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3503 href="http://dx.doi.org/10.21037/atm.2016.12.67">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3506 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5253283">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d12245e3515 class=n-a></a>Qin Y, Roszik J, Chattopadhyay C, <i> et al.</i>: Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. <i>Mol Cancer Ther.</i> 2016; <b>15</b>(10): 2442–2454. <a target=xrefwindow id=d12245e3526 href="http://www.ncbi.nlm.nih.gov/pubmed/27458138">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3529 href="http://dx.doi.org/10.1158/1535-7163.MCT-15-0963">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3533 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5079683">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d12245e3542 class=n-a></a>Jahangiri A, De Lay M, Miller LM, <i> et al.</i>: Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. <i>Clin Cancer Res.</i> 2013; <b>19</b>(7): 1773–83. <a target=xrefwindow id=d12245e3553 href="http://www.ncbi.nlm.nih.gov/pubmed/23307858">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3556 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-1281">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3560 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3618605">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727181945"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3569 class=n-a></a>Daudigeos-Dubus E, Le Dret L, Bawa O, <i> et al.</i>: Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. <i>Int J Oncol.</i> 2017; <b>50</b>(1): 203–211. <a target=xrefwindow id=d12245e3580 href="http://www.ncbi.nlm.nih.gov/pubmed/27922668">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3583 href="http://dx.doi.org/10.3892/ijo.2016.3792">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727181945">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d12245e3596 class=n-a></a>Coleman RL, Brady MF, Herzog TJ, <i> et al.</i>: Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(6): 779–791. <a target=xrefwindow id=d12245e3607 href="http://www.ncbi.nlm.nih.gov/pubmed/28438473">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3610 href="http://dx.doi.org/10.1016/S1470-2045(17)30279-6">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5715461">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d12245e3623 class=n-a></a>Marth C, Vergote I, Scambia G, <i> et al.</i>: ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>Eur J Cancer.</i> 2017; <b>70</b>: 111–121. <a target=xrefwindow id=d12245e3634 href="http://www.ncbi.nlm.nih.gov/pubmed/27914241">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3637 href="http://dx.doi.org/10.1016/j.ejca.2016.09.004">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d12245e3647 class=n-a></a>Monk BJ, Poveda A, Vergote I, <i> et al.</i>: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(8): 799–808. <a target=xrefwindow id=d12245e3658 href="http://www.ncbi.nlm.nih.gov/pubmed/24950985">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3661 href="http://dx.doi.org/10.1016/S1470-2045(14)70244-X">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716997867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3670 class=n-a></a>Aghajanian C, Blank SV, Goff BA, <i> et al.</i>: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. <i>J Clin Oncol.</i> 2012; <b>30</b>(17): 2039–45. <a target=xrefwindow id=d12245e3681 href="http://www.ncbi.nlm.nih.gov/pubmed/22529265">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3684 href="http://dx.doi.org/10.1200/JCO.2012.42.0505">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3688 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3646321">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716997867">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d12245e3701 class=n-a></a>Aghajanian C, Goff B, Nycum LR, <i> et al.</i>: Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. <i>Gynecol Oncol.</i> 2015; <b>139</b>(1): 10–6. <a target=xrefwindow id=d12245e3712 href="http://www.ncbi.nlm.nih.gov/pubmed/26271155">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3715 href="http://dx.doi.org/10.1016/j.ygyno.2015.08.004">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3719 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4993045">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718312260"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3728 class=n-a></a>Pujade-Lauraine E, Hilpert F, Weber B, <i> et al.</i>: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. <i>J Clin Oncol.</i> 2014; <b>32</b>(13): 1302–8. <a target=xrefwindow id=d12245e3739 href="http://www.ncbi.nlm.nih.gov/pubmed/24637997">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3742 href="http://dx.doi.org/10.1200/JCO.2013.51.4489">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718312260">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d12245e3755 class=n-a></a>Oza AM, Cook AD, Pfisterer J, <i> et al.</i>: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(8): 928–36. <a target=xrefwindow id=d12245e3766 href="http://www.ncbi.nlm.nih.gov/pubmed/26115797">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3769 href="http://dx.doi.org/10.1016/S1470-2045(15)00086-8">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3773 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4648090">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d12245e3782 class=n-a></a>Ledermann JA, Embleton AC, Raja F, <i> et al.</i>: Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet.</i> 2016; <b>387</b>(10023): 1066–74. <a target=xrefwindow id=d12245e3793 href="http://www.ncbi.nlm.nih.gov/pubmed/27025186">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3796 href="http://dx.doi.org/10.1016/S0140-6736(15)01167-8">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726377012"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3806 class=n-a></a>Monk BJ, Sill MW, Walker JL, <i> et al.</i>: Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>J Clin Oncol.</i> 2016; <b>34</b>(19): 2279–86. <a target=xrefwindow id=d12245e3817 href="http://www.ncbi.nlm.nih.gov/pubmed/27217446">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3820 href="http://dx.doi.org/10.1200/JCO.2015.65.8153">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3824 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4962710">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726377012">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d12245e3837 class=n-a></a>du Bois A, Kristensen G, Ray-Coquard I, <i> et al.</i>: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(1): 78–89. <a target=xrefwindow id=d12245e3848 href="http://www.ncbi.nlm.nih.gov/pubmed/26590673">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3851 href="http://dx.doi.org/10.1016/S1470-2045(15)00366-6">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718283106"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e3860 class=n-a></a>Tewari KS, Sill MW, Long HJ 3rd, <i> et al.</i>: Improved survival with bevacizumab in advanced cervical cancer. <i>N Engl J Med.</i> 2014; <b>370</b>(8): 734–43. <a target=xrefwindow id=d12245e3871 href="http://www.ncbi.nlm.nih.gov/pubmed/24552320">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3874 href="http://dx.doi.org/10.1056/NEJMoa1309748">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3878 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4010094">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718283106">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d12245e3891 class=n-a></a>Symonds RP, Gourley C, Davidson S, <i> et al.</i>: Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(15): 1515–24. <a target=xrefwindow id=d12245e3902 href="http://www.ncbi.nlm.nih.gov/pubmed/26474517">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3905 href="http://dx.doi.org/10.1016/S1470-2045(15)00220-X">Publisher Full Text </a> | <a target=xrefwindow id=d12245e3909 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4705431">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d12245e3918 class=n-a></a>Takeda M, Yamanaka T, Seto T, <i> et al.</i>: Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial. <i>Cancer.</i> 2016; <b>122</b>(7): 1050–9. <a target=xrefwindow id=d12245e3929 href="http://www.ncbi.nlm.nih.gov/pubmed/26828788">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3932 href="http://dx.doi.org/10.1002/cncr.29893">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d12245e3941 class=n-a></a>Zhou C, Wu YL, Chen G, <i> et al.</i>: BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>J Clin Oncol.</i> 2015; <b>33</b>(19): 2197–204. <a target=xrefwindow id=d12245e3952 href="http://www.ncbi.nlm.nih.gov/pubmed/26014294">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3955 href="http://dx.doi.org/10.1200/JCO.2014.59.4424">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d12245e3965 class=n-a></a>Pujol JL, Lavole A, Quoix E, <i> et al.</i>: Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. <i>Ann Oncol.</i> 2015; <b>26</b>(5): 908–14. <a target=xrefwindow id=d12245e3976 href="http://www.ncbi.nlm.nih.gov/pubmed/25688059">PubMed Abstract </a> | <a target=xrefwindow id=d12245e3979 href="http://dx.doi.org/10.1093/annonc/mdv065">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d12245e3988 class=n-a></a>Tournigand C, Chibaudel B, Samson B, <i> et al.</i>: Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(15): 1493–505. <a target=xrefwindow id=d12245e3999 href="http://www.ncbi.nlm.nih.gov/pubmed/26474518">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4002 href="http://dx.doi.org/10.1016/S1470-2045(15)00216-8">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d12245e4011 class=n-a></a>Tabernero J, Yoshino T, Cohn AL, <i> et al.</i>: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncol.</i> 2015; <b>16</b>(5): 499–508. <a target=xrefwindow id=d12245e4022 href="http://www.ncbi.nlm.nih.gov/pubmed/25877855">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4025 href="http://dx.doi.org/10.1016/S1470-2045(15)70127-0">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d12245e4034 class=n-a></a>Martín M, Loibl S, von Minckwitz G, <i> et al.</i>: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. <i>J Clin Oncol.</i> 2015; <b>33</b>(9): 1045–52. <a target=xrefwindow id=d12245e4045 href="http://www.ncbi.nlm.nih.gov/pubmed/25691671">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4048 href="http://dx.doi.org/10.1200/JCO.2014.57.2388">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d12245e4057 class=n-a></a>Balana C, De Las Penas R, Sepúlveda JM, <i> et al.</i>: Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. <i>J Neurooncol.</i> 2016; <b>127</b>(3): 569–79. <a target=xrefwindow id=d12245e4068 href="http://www.ncbi.nlm.nih.gov/pubmed/26847813">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4071 href="http://dx.doi.org/10.1007/s11060-016-2065-5">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d12245e4080 class=n-a></a>Haas NB, Manola J, Uzzo RG, <i> et al.</i>: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet.</i> 2016; <b>387</b>(10032): 2008–16. <a target=xrefwindow id=d12245e4091 href="http://www.ncbi.nlm.nih.gov/pubmed/26969090">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4094 href="http://dx.doi.org/10.1016/S0140-6736(16)00559-6">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4098 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4878938">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d12245e4108 class=n-a></a>Choueiri TK, Halabi S, Sanford BL, <i> et al.</i>: Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>J Clin Oncol.</i> 2017; <b>35</b>(6): 591–597. <a target=xrefwindow id=d12245e4119 href="http://www.ncbi.nlm.nih.gov/pubmed/28199818">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4122 href="http://dx.doi.org/10.1200/JCO.2016.70.7398">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4126 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5455807">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d12245e4135 class=n-a></a>Choueiri TK, Escudier B, Powles T, <i> et al.</i>: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(7): 917–27. <a target=xrefwindow id=d12245e4146 href="http://www.ncbi.nlm.nih.gov/pubmed/27279544">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4149 href="http://dx.doi.org/10.1016/S1470-2045(16)30107-3">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d12245e4158 class=n-a></a>Daud A, Kluger HM, Kurzrock R, <i> et al.</i>: Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>Br J Cancer.</i> 2017; <b>116</b>(4): 432–440. <a target=xrefwindow id=d12245e4169 href="http://www.ncbi.nlm.nih.gov/pubmed/28103611">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4172 href="http://dx.doi.org/10.1038/bjc.2016.419">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5318966">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d12245e4185 class=n-a></a>Zalcman G, Mazieres J, Margery J, <i> et al.</i>: Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet.</i> 2016; <b>387</b>(10026): 1405–14. <a target=xrefwindow id=d12245e4196 href="http://www.ncbi.nlm.nih.gov/pubmed/26719230">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4199 href="http://dx.doi.org/10.1016/S0140-6736(15)01238-6">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d12245e4208 class=n-a></a>Hensley ML, Miller A, O'Malley DM, <i> et al.</i>: Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. <i>J Clin Oncol.</i> 2015; <b>33</b>(10): 1180–5. <a target=xrefwindow id=d12245e4219 href="http://www.ncbi.nlm.nih.gov/pubmed/25713428">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4222 href="http://dx.doi.org/10.1200/JCO.2014.58.3781">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4226 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4372854">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d12245e4235 class=n-a></a>Kawai A, Araki N, Hiraga H, <i> et al.</i>: A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. <i>Jpn J Clin Oncol.</i> 2016; <b>46</b>(3): 248–53. <a target=xrefwindow id=d12245e4246 href="http://www.ncbi.nlm.nih.gov/pubmed/26864131">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4249 href="http://dx.doi.org/10.1093/jjco/hyv184">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4253 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4777611">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d12245e4263 class=n-a></a>Sidorov M, Jahangiri A, Han SW, <i> et al.</i>: 340 c-Met/β1 Integrin: A Receptor Complex Driving Invasive Glioblastoma Resistance to Antiangiogenic Therapy. <i>Neurosurgery.</i> 2016; <b>63 Suppl1</b>: 199–200. <a target=xrefwindow id=d12245e4274 href="http://www.ncbi.nlm.nih.gov/pubmed/27399538">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4277 href="http://dx.doi.org/10.1227/01.neu.0000489829.38251.85">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d12245e4286 class=n-a></a>Depner C, Zum Buttel H, Böğürcü N, <i> et al.</i>: EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance. <i>Nat Commun.</i> 2016; <b>7</b>: 12329. <a target=xrefwindow id=d12245e4297 href="http://www.ncbi.nlm.nih.gov/pubmed/27470974">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4300 href="http://dx.doi.org/10.1038/ncomms12329">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4304 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4974575">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d12245e4313 class=n-a></a>Jahangiri A, Chen W, Yagnik G, <i> et al.</i>: 333 Obtaining the Genetic Fingerprint of Resistance to Glioblastoma Through a Novel Multigenerational Xenograft Model. <i>Neurosurgery.</i> 2016; <b>63 Suppl1</b>: 197. <a target=xrefwindow id=d12245e4324 href="http://www.ncbi.nlm.nih.gov/pubmed/27399531">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4327 href="http://dx.doi.org/10.1227/01.neu.0000489822.13595.ca">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d12245e4336 class=n-a></a>Sennino B, Ishiguro-Oonuma T, Wei Y, <i> et al.</i>: Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. <i>Cancer Discov.</i> 2012; <b>2</b>(3): 270–87. <a target=xrefwindow id=d12245e4347 href="http://www.ncbi.nlm.nih.gov/pubmed/22585997">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4350 href="http://dx.doi.org/10.1158/2159-8290.CD-11-0240">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4354 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3354652">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717952877"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4363 class=n-a></a>Lu KV, Chang JP, Parachoniak CA, <i> et al.</i>: VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. <i>Cancer Cell.</i> 2012; <b>22</b>(1): 21–35. <a target=xrefwindow id=d12245e4374 href="http://www.ncbi.nlm.nih.gov/pubmed/22789536">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4377 href="http://dx.doi.org/10.1016/j.ccr.2012.05.037">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4381 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4068350">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717952877">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/732415195"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4394 class=n-a></a>Escudier B, Powles T, Motzer RJ, <i> et al.</i>: Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>J Clin Oncol.</i> 2018; <b>36</b>(8): 765–772. <a target=xrefwindow id=d12245e4405 href="http://www.ncbi.nlm.nih.gov/pubmed/29309249">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4408 href="http://dx.doi.org/10.1200/JCO.2017.74.7352">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/732415195">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717971615"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4422 class=n-a></a>Choueiri TK, Vaishampayan U, Rosenberg JE, <i> et al.</i>: Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. <i>J Clin Oncol.</i> 2013; <b>31</b>(2): 181–6. <a target=xrefwindow id=d12245e4433 href="http://www.ncbi.nlm.nih.gov/pubmed/23213094">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4436 href="http://dx.doi.org/10.1200/JCO.2012.43.3383">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4440 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3532390">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717971615">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d12245e4453 class=n-a></a>Delgado-Bellido D, Serrano-Saenz S, Fernández-Cortés M, <i> et al.</i>: Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. <i>Mol Cancer.</i> 2017; <b>16</b>(1): 65. <a target=xrefwindow id=d12245e4464 href="http://www.ncbi.nlm.nih.gov/pubmed/28320399">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4467 href="http://dx.doi.org/10.1186/s12943-017-0631-x">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4471 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5359927">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d12245e4480 class=n-a></a>Qiao L, Liang N, Zhang J, <i> et al.</i>: Advanced research on vasculogenic mimicry in cancer. <i>J Cell Mol Med.</i> 2015; <b>19</b>(2): 315–26. <a target=xrefwindow id=d12245e4491 href="http://www.ncbi.nlm.nih.gov/pubmed/25598425">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4494 href="http://dx.doi.org/10.1111/jcmm.12496">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4498 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4407602">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d12245e4507 class=n-a></a>Li S, Meng W, Guan Z, <i> et al.</i>: The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment. <i>Biomed Pharmacother.</i> 2016; <b>80</b>: 127–35. <a target=xrefwindow id=d12245e4518 href="http://www.ncbi.nlm.nih.gov/pubmed/27133049">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4521 href="http://dx.doi.org/10.1016/j.biopha.2016.03.010">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726663502"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4530 class=n-a></a>Serova M, Tijeras-Raballand A, Dos Santos C, <i> et al.</i>: Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. <i>Oncotarget.</i> 2016; <b>7</b>(25): 38467–86. <a target=xrefwindow id=d12245e4541 href="http://www.ncbi.nlm.nih.gov/pubmed/27509260">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4544 href="http://dx.doi.org/10.18632/oncotarget.9542">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4548 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5122404">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726663502">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d12245e4561 class=n-a></a>DeLisser HM, Christofidou-Solomidou M, Strieter RM, <i> et al.</i>: Involvement of endothelial PECAM-1/CD31 in angiogenesis. <i>Am J Pathol.</i> 1997; <b>151</b>(3): 671–7. <a target=xrefwindow id=d12245e4572 href="http://www.ncbi.nlm.nih.gov/pubmed/9284815">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4575 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1857836">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d12245e4585 class=n-a></a>Dunleavey JM, Xiao L, Thompson J, <i> et al.</i>: Vascular channels formed by subpopulations of PECAM1<sup>+</sup> melanoma cells. <i>Nat Commun.</i> 2014; <b>5</b>: 5200. <a target=xrefwindow id=d12245e4599 href="http://www.ncbi.nlm.nih.gov/pubmed/25335460">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4603 href="http://dx.doi.org/10.1038/ncomms6200">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4606 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4261234">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d12245e4615 class=n-a></a>Sun H, Zhang D, Yao Z, <i> et al.</i>: Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. <i>Cancer Biol Ther.</i> 2017; <b>18</b>(4): 205–213. <a target=xrefwindow id=d12245e4626 href="http://www.ncbi.nlm.nih.gov/pubmed/28278077">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4629 href="http://dx.doi.org/10.1080/15384047.2017.1294288">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4633 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5450737">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d12245e4642 class=n-a></a>Macklin PS, McAuliffe J, Pugh CW, <i> et al.</i>: Hypoxia and HIF pathway in cancer and the placenta. <i>Placenta.</i> 2017; <b>56</b>: 8–13. <a target=xrefwindow id=d12245e4653 href="http://www.ncbi.nlm.nih.gov/pubmed/28330647">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4656 href="http://dx.doi.org/10.1016/j.placenta.2017.03.010">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d12245e4665 class=n-a></a>Donnem T, Hu J, Ferguson M, <i> et al.</i>: Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? <i>Cancer Med.</i> 2013; <b>2</b>(4): 427–36. <a target=xrefwindow id=d12245e4676 href="http://www.ncbi.nlm.nih.gov/pubmed/24156015">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4679 href="http://dx.doi.org/10.1002/cam4.105">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4683 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3799277">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d12245e4692 class=n-a></a>Pinto MP, Sotomayor P, Carrasco-Avino G, <i> et al.</i>: Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells. <i>Int J Mol Sci</i> 2016; <b>17</b>(9): pii: E1489. <a target=xrefwindow id=d12245e4703 href="http://www.ncbi.nlm.nih.gov/pubmed/27608016">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4706 href="http://dx.doi.org/10.3390/ijms17091489">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4710 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5037767">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d12245e4719 class=n-a></a>Jeong HS, Jones D, Liao S, <i> et al.</i>: Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. <i>J Natl Cancer Inst.</i> 2015; <b>107</b>(9): pii: djv155. <a target=xrefwindow id=d12245e4730 href="http://www.ncbi.nlm.nih.gov/pubmed/26063793">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4733 href="http://dx.doi.org/10.1093/jnci/djv155">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4737 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4651102">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d12245e4747 class=n-a></a>Leenders WP, Küsters B, Verrijp K, <i> et al.</i>: Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. <i>Clin Cancer Res.</i> 2004; <b>10</b>(18 Pt 1): 6222–30. <a target=xrefwindow id=d12245e4758 href="http://www.ncbi.nlm.nih.gov/pubmed/15448011">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4761 href="http://dx.doi.org/10.1158/1078-0432.CCR-04-0823">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d12245e4770 class=n-a></a>Rubenstein JL, Kim J, Ozawa T, <i> et al.</i>: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. <i>Neoplasia.</i> 2000; <b>2</b>(4): 306–14. <a target=xrefwindow id=d12245e4781 href="http://www.ncbi.nlm.nih.gov/pubmed/11005565">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4784 href="http://dx.doi.org/10.1038/sj.neo.7900102">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4788 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1550290">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726997775"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4797 class=n-a></a>Bridgeman VL, Vermeulen PB, Foo S, <i> et al.</i>: Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. <i>J Pathol.</i> 2017; <b>241</b>(3): 362–374. <a target=xrefwindow id=d12245e4808 href="http://www.ncbi.nlm.nih.gov/pubmed/27859259">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4811 href="http://dx.doi.org/10.1002/path.4845">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4815 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5248628">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726997775">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d12245e4828 class=n-a></a>Szabo V, Bugyik E, Dezso K, <i> et al.</i>: Mechanism of tumour vascularization in experimental lung metastases. <i>J Pathol.</i> 2015; <b>235</b>(3): 384–96. <a target=xrefwindow id=d12245e4839 href="http://www.ncbi.nlm.nih.gov/pubmed/25319725">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4842 href="http://dx.doi.org/10.1002/path.4464">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726275809"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4851 class=n-a></a>Kuczynski EA, Yin M, Bar-Zion A, <i> et al.</i>: Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. <i>J Natl Cancer Inst.</i> 2016; <b>108</b>(8). djw030. <a target=xrefwindow id=d12245e4862 href="http://www.ncbi.nlm.nih.gov/pubmed/27059374">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4865 href="http://dx.doi.org/10.1093/jnci/djw030">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4869 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5017954">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726275809">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1157541"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4882 class=n-a></a>Pàez-Ribes M, Allen E, Hudock J, <i> et al.</i>: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. <i>Cancer Cell.</i> 2009; <b>15</b>(3): 220–31. <a target=xrefwindow id=d12245e4893 href="http://www.ncbi.nlm.nih.gov/pubmed/19249680">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4896 href="http://dx.doi.org/10.1016/j.ccr.2009.01.027">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2874829">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1157541">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d12245e4914 class=n-a></a>van Malenstein H, Dekervel J, Verslype C, <i> et al.</i>: Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. <i>Cancer Lett.</i> 2013; <b>329</b>(1): 74–83. <a target=xrefwindow id=d12245e4925 href="http://www.ncbi.nlm.nih.gov/pubmed/23111106">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4928 href="http://dx.doi.org/10.1016/j.canlet.2012.10.021">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726854995"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4937 class=n-a></a>Frentzas S, Simoneau E, Bridgeman VL, <i> et al.</i>: Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. <i>Nat Med.</i> 2016; <b>22</b>(11): 1294–1302. <a target=xrefwindow id=d12245e4948 href="http://www.ncbi.nlm.nih.gov/pubmed/27748747">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4951 href="http://dx.doi.org/10.1038/nm.4197">Publisher Full Text </a> | <a target=xrefwindow id=d12245e4955 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5104270">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726854995">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d12245e4968 class=n-a></a>Nakajima EC, Van Houten B: Metabolic symbiosis in cancer: refocusing the Warburg lens. <i>Mol Carcinog.</i> 2013; <b>52</b>(5): 329–37. <a target=xrefwindow id=d12245e4976 href="http://www.ncbi.nlm.nih.gov/pubmed/22228080">PubMed Abstract </a> | <a target=xrefwindow id=d12245e4979 href="http://dx.doi.org/10.1002/mc.21863">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717978653"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e4988 class=n-a></a>Guillaumond F, Leca J, Olivares O, <i> et al.</i>: Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. <i>Proc Natl Acad Sci U S A.</i> 2013; <b>110</b>(10): 3919–24. <a target=xrefwindow id=d12245e4999 href="http://www.ncbi.nlm.nih.gov/pubmed/23407165">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5002 href="http://dx.doi.org/10.1073/pnas.1219555110">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5006 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3593894">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717978653">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d12245e5019 class=n-a></a>Pisarsky L, Bill R, Fagiani E, <i> et al.</i>: Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy. <i>Cell Rep.</i> 2016; <b>15</b>(6): 1161–74. <a target=xrefwindow id=d12245e5030 href="http://www.ncbi.nlm.nih.gov/pubmed/27134168">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5033 href="http://dx.doi.org/10.1016/j.celrep.2016.04.028">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5037 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4870473">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726325892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5046 class=n-a></a>Allen E, Miéville P, Warren CM, <i> et al.</i>: Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. <i>Cell Rep.</i> 2016; <b>15</b>(6): 1144–60. <a target=xrefwindow id=d12245e5057 href="http://www.ncbi.nlm.nih.gov/pubmed/27134166">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5060 href="http://dx.doi.org/10.1016/j.celrep.2016.04.029">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5064 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4872464">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726325892">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726325879"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5078 class=n-a></a>Jiménez-Valerio G, Martínez-Lozano M, Bassani N, <i> et al.</i>: Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. <i>Cell Rep.</i> 2016; <b>15</b>(6): 1134–43. <a target=xrefwindow id=d12245e5089 href="http://www.ncbi.nlm.nih.gov/pubmed/27134180">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5092 href="http://dx.doi.org/10.1016/j.celrep.2016.04.015">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5096 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4870515">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726325879">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727280600"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5109 class=n-a></a>Chen CH, Fong LWR, Yu E, <i> et al.</i>: Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target. <i>Oncogene.</i> 2017; <b>36</b>(25): 3588–3598. <a target=xrefwindow id=d12245e5120 href="http://www.ncbi.nlm.nih.gov/pubmed/28166200">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5123 href="http://dx.doi.org/10.1038/onc.2016.510">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727280600">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d12245e5136 class=n-a></a>McElroy GS, Chandel NS: Mitochondria control acute and chronic responses to hypoxia. <i>Exp Cell Res.</i> 2017; <b>356</b>(2): 217–222. <a target=xrefwindow id=d12245e5144 href="http://www.ncbi.nlm.nih.gov/pubmed/28327410">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5147 href="http://dx.doi.org/10.1016/j.yexcr.2017.03.034">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5474758">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727460985"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5159 class=n-a></a>Harel S, Mayaki D, Sanchez V, <i> et al.</i>: NOX2, NOX4, and mitochondrial-derived reactive oxygen species contribute to angiopoietin-1 signaling and angiogenic responses in endothelial cells. <i>Vascul Pharmacol.</i> 2017; <b>92</b>: 22–32. <a target=xrefwindow id=d12245e5170 href="http://www.ncbi.nlm.nih.gov/pubmed/28351775">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5173 href="http://dx.doi.org/10.1016/j.vph.2017.03.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727460985">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726419868"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5186 class=n-a></a>Navarro P, Bueno MJ, Zagorac I, <i> et al.</i>: Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. <i>Cell Rep.</i> 2016; <b>15</b>(12): 2705–18. <a target=xrefwindow id=d12245e5197 href="http://www.ncbi.nlm.nih.gov/pubmed/27292634">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5200 href="http://dx.doi.org/10.1016/j.celrep.2016.05.052">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726419868">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d12245e5213 class=n-a></a>Burr SP, Costa AS, Grice GL, <i> et al.</i>: Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1α Stability in Aerobic Conditions. <i>Cell Metab.</i> 2016; <b>24</b>(5): 740–752. <a target=xrefwindow id=d12245e5224 href="http://www.ncbi.nlm.nih.gov/pubmed/27923773">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5227 href="http://dx.doi.org/10.1016/j.cmet.2016.09.015">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5231 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5106373">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1158596"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5241 class=n-a></a>Ebos JM, Lee CR, Cruz-Munoz M, <i> et al.</i>: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. <i>Cancer Cell.</i> 2009; <b>15</b>(3): 232–9. <a target=xrefwindow id=d12245e5252 href="http://www.ncbi.nlm.nih.gov/pubmed/19249681">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5255 href="http://dx.doi.org/10.1016/j.ccr.2009.01.021">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5259 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4540346">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1158596">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d12245e5272 class=n-a></a>Singleton DC, Rouhi P, Zois CE, <i> et al.</i>: Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. <i>Oncogene.</i> 2015; <b>34</b>(36): 4713–22. <a target=xrefwindow id=d12245e5283 href="http://www.ncbi.nlm.nih.gov/pubmed/25486436">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5286 href="http://dx.doi.org/10.1038/onc.2014.396">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5290 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4430306">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d12245e5299 class=n-a></a>Hwang-Verslues WW, Chang PH, Jeng YM, <i> et al.</i>: Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. <i>Proc Natl Acad Sci U S A.</i> 2013; <b>110</b>(30): 12331–6. <a target=xrefwindow id=d12245e5310 href="http://www.ncbi.nlm.nih.gov/pubmed/23836662">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5313 href="http://dx.doi.org/10.1073/pnas.1222684110">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5317 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3725072">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d12245e5326 class=n-a></a>Chaturvedi P, Gilkes DM, Takano N, <i> et al.</i>: Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(20): E2120–9. <a target=xrefwindow id=d12245e5337 href="http://www.ncbi.nlm.nih.gov/pubmed/24799675">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5340 href="http://dx.doi.org/10.1073/pnas.1406655111">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5344 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4034192">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d12245e5353 class=n-a></a>Gabrusiewicz K, Liu D, Cortes-Santiago N, <i> et al.</i>: Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. <i>Oncotarget.</i> 2014; <b>5</b>(8): 2208–20. <a target=xrefwindow id=d12245e5364 href="http://www.ncbi.nlm.nih.gov/pubmed/24809734">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5367 href="http://dx.doi.org/10.18632/oncotarget.1893">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5371 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4039157">Free Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d12245e5380 class=n-a></a>Huijbers EJ, van Beijnum JR, Thijssen VL, <i> et al.</i>: Role of the tumor stroma in resistance to anti-angiogenic therapy. <i>Drug Resist Updat.</i> 2016; <b>25</b>: 26–37. <a target=xrefwindow id=d12245e5391 href="http://www.ncbi.nlm.nih.gov/pubmed/27155374">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5394 href="http://dx.doi.org/10.1016/j.drup.2016.02.002">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726015555"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5404 class=n-a></a>Scholz A, Harter PN, Cremer S, <i> et al.</i>: Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. <i>EMBO Mol Med.</i> 2016; <b>8</b>(1): 39–57. <a target=xrefwindow id=d12245e5415 href="http://www.ncbi.nlm.nih.gov/pubmed/26666269">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5418 href="http://dx.doi.org/10.15252/emmm.201505505">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5422 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4718155">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726015555">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d12245e5435 class=n-a></a>Hida K, Maishi N, Sakurai Y, <i> et al.</i>: Heterogeneity of tumor endothelial cells and drug delivery. <i>Adv Drug Deliv Rev.</i> 2016; <b>99</b>(Pt B): 140–7. <a target=xrefwindow id=d12245e5446 href="http://www.ncbi.nlm.nih.gov/pubmed/26626622">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5449 href="http://dx.doi.org/10.1016/j.addr.2015.11.008">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727331573"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5458 class=n-a></a>Xu J, Liang J, Meng YM, <i> et al.</i>: Vascular CXCR4 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma. <i>Clin Cancer Res.</i> 2017; <b>23</b>(15): 4482–4492. <a target=xrefwindow id=d12245e5469 href="http://www.ncbi.nlm.nih.gov/pubmed/28223275">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5472 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-2131">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727331573">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d12245e5485 class=n-a></a>Mitsuhashi A, Goto H, Saijo A, <i> et al.</i>: Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. <i>Nat Commun.</i> 2015; <b>6</b>: 8792. <a target=xrefwindow id=d12245e5496 href="http://www.ncbi.nlm.nih.gov/pubmed/26635184">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5499 href="http://dx.doi.org/10.1038/ncomms9792">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5503 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4686833">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d12245e5512 class=n-a></a>Kioi M, Vogel H, Schultz G, <i> et al.</i>: Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. <i>J Clin Invest.</i> 2010; <b>120</b>(3): 694–705. <a target=xrefwindow id=d12245e5523 href="http://www.ncbi.nlm.nih.gov/pubmed/20179352">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5526 href="http://dx.doi.org/10.1172/JCI40283">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5530 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2827954">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726564587"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5539 class=n-a></a>Shaaban S, Alsulami M, Arbab SA, <i> et al.</i>: Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma. <i>Int J Cancer Res.</i> 2016; <b>12</b>(2): 69–81. <a target=xrefwindow id=d12245e5550 href="http://www.ncbi.nlm.nih.gov/pubmed/27429653">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5553 href="http://dx.doi.org/10.3923/ijcr.2016.69.81">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5557 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4945124">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726564587">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d12245e5571 class=n-a></a>Ali MM, Kumar S, Shankar A, <i> et al.</i>: Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. <i>Transl Oncol.</i> 2013; <b>6</b>(6): 660–9. <a target=xrefwindow id=d12245e5582 href="http://www.ncbi.nlm.nih.gov/pubmed/24466368">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5585 href="http://dx.doi.org/10.1593/tlo.13559">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5589 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3890700">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d12245e5598 class=n-a></a>Achyut BR, Shankar A, Iskander AS, <i> et al.</i>: Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks. <i>Cancer Lett.</i> 2015; <b>369</b>(2): 416–26. <a target=xrefwindow id=d12245e5609 href="http://www.ncbi.nlm.nih.gov/pubmed/26404753">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5612 href="http://dx.doi.org/10.1016/j.canlet.2015.09.004">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5616 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4686232">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718206958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5625 class=n-a></a>Casazza A, Laoui D, Wenes M, <i> et al.</i>: Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. <i>Cancer Cell.</i> 2013; <b>24</b>(6): 695–709. <a target=xrefwindow id=d12245e5636 href="http://www.ncbi.nlm.nih.gov/pubmed/24332039">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5639 href="http://dx.doi.org/10.1016/j.ccr.2013.11.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718206958">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727328182"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5652 class=n-a></a>Castro BA, Flanigan P, Jahangiri A, <i> et al.</i>: Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. <i>Oncogene.</i> 2017; <b>36</b>(26): 3749–3759. <a target=xrefwindow id=d12245e5663 href="http://www.ncbi.nlm.nih.gov/pubmed/28218903">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5666 href="http://dx.doi.org/10.1038/onc.2017.1">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5670 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5491354">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727328182">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10282956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5683 class=n-a></a>Mazzieri R, Pucci F, Moi D, <i> et al.</i>: Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. <i>Cancer Cell.</i> 2011; <b>19</b>(4): 512–26. <a target=xrefwindow id=d12245e5694 href="http://www.ncbi.nlm.nih.gov/pubmed/21481792">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5697 href="http://dx.doi.org/10.1016/j.ccr.2011.02.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10282956">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4390991"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5710 class=n-a></a>Fantin A, Vieira JM, Gestri G, <i> et al.</i>: Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. <i>Blood.</i> 2010; <b>116</b>(5): 829–40. <a target=xrefwindow id=d12245e5721 href="http://www.ncbi.nlm.nih.gov/pubmed/20404134">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5724 href="http://dx.doi.org/10.1182/blood-2009-12-257832">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5728 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2938310">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4390991">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d12245e5742 class=n-a></a>Rigamonti N, Kadioglu E, Keklikoglou I, <i> et al.</i>: Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. <i>Cell Rep.</i> 2014; <b>8</b>(3): 696–706. <a target=xrefwindow id=d12245e5753 href="http://www.ncbi.nlm.nih.gov/pubmed/25088418">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5756 href="http://dx.doi.org/10.1016/j.celrep.2014.06.059">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726263820"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5765 class=n-a></a>Peterson TE, Kirkpatrick ND, Huang Y, <i> et al.</i>: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. <i>Proc Natl Acad Sci U S A.</i> 2016; <b>113</b>(16): 4470–5. <a target=xrefwindow id=d12245e5776 href="http://www.ncbi.nlm.nih.gov/pubmed/27044097">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5779 href="http://dx.doi.org/10.1073/pnas.1525349113">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5783 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4843449">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726263820">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732337116"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5796 class=n-a></a>Reardon DA, Lassman AB, Schiff D, <i> et al.</i>: Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer.</i> 2017. <a target=xrefwindow id=d12245e5804 href="http://www.ncbi.nlm.nih.gov/pubmed/29266174">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5807 href="http://dx.doi.org/10.1002/cncr.31172">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732337116">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d12245e5820 class=n-a></a>Stapor PC, Sweat RS, Dashti DC, <i> et al.</i>: Pericyte dynamics during angiogenesis: new insights from new identities. <i>J Vasc Res.</i> 2014; <b>51</b>(3): 163–74. <a target=xrefwindow id=d12245e5831 href="http://www.ncbi.nlm.nih.gov/pubmed/24853910">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5834 href="http://dx.doi.org/10.1159/000362276">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4149862">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d12245e5847 class=n-a></a>Caporali A, Martello A, Miscianinov V, <i> et al.</i>: Contribution of pericyte paracrine regulation of the endothelium to angiogenesis. <i>Pharmacol Ther.</i> 2017; <b>171</b>: 56–64. <a target=xrefwindow id=d12245e5858 href="http://www.ncbi.nlm.nih.gov/pubmed/27742570">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5861 href="http://dx.doi.org/10.1016/j.pharmthera.2016.10.001">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d12245e5870 class=n-a></a>Kang E, Shin JW: Pericyte-targeting drug delivery and tissue engineering. <i>Int J Nanomedicine.</i> 2016; <b>11</b>: 2397–406. <a target=xrefwindow id=d12245e5878 href="http://www.ncbi.nlm.nih.gov/pubmed/27313454">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5881 href="http://dx.doi.org/10.2147/IJN.S105274">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5884 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4892861">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727817873"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5894 class=n-a></a>Teichert M, Milde L, Holm A, <i> et al.</i>: Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. <i>Nat Commun.</i> 2017; <b>8</b>: 16106. <a target=xrefwindow id=d12245e5905 href="http://www.ncbi.nlm.nih.gov/pubmed/28719590">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5908 href="http://dx.doi.org/10.1038/ncomms16106">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5912 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5520106">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727817873">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d12245e5925 class=n-a></a>Herbert SP, Stainier DY: Molecular control of endothelial cell behaviour during blood vessel morphogenesis. <i>Nat Rev Mol Cell Biol.</i> 2011; <b>12</b>(9): 551–64. <a target=xrefwindow id=d12245e5933 href="http://www.ncbi.nlm.nih.gov/pubmed/21860391">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5936 href="http://dx.doi.org/10.1038/nrm3176">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5939 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3319719">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727754486"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5948 class=n-a></a>Hosono J, Morikawa S, Ezaki T, <i> et al.</i>: Pericytes promote abnormal tumor angiogenesis in a rat RG2 glioma model. <i>Brain Tumor Pathol.</i> 2017; <b>34</b>(3): 120–129. <a target=xrefwindow id=d12245e5959 href="http://www.ncbi.nlm.nih.gov/pubmed/28646266">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5962 href="http://dx.doi.org/10.1007/s10014-017-0291-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727754486">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727728896"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e5975 class=n-a></a>Zhang L, Wang Y, Rashid MH, <i> et al.</i>: Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis. <i>Oncotarget.</i> 2017; <b>8</b>(31): 51591–51607. <a target=xrefwindow id=d12245e5986 href="http://www.ncbi.nlm.nih.gov/pubmed/28881671">PubMed Abstract </a> | <a target=xrefwindow id=d12245e5989 href="http://dx.doi.org/10.18632/oncotarget.18196">Publisher Full Text </a> | <a target=xrefwindow id=d12245e5993 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5584272">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727728896">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d12245e6006 class=n-a></a>Bergers G, Song S, Meyer-Morse N, <i> et al.</i>: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. <i>J Clin Invest.</i> 2003; <b>111</b>(9): 1287–95. <a target=xrefwindow id=d12245e6017 href="http://www.ncbi.nlm.nih.gov/pubmed/12727920 ">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6020 href="http://dx.doi.org/10.1172/JCI17929">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6024 href="http://www.ncbi.nlm.nih.gov/pmc/articles/154450">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d12245e6033 class=n-a></a>Nisancioglu MH, Betsholtz C, Genové G: The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. <i>Cancer Res.</i> 2010; <b>70</b>(12): 5109–15. <a target=xrefwindow id=d12245e6041 href="http://www.ncbi.nlm.nih.gov/pubmed/20501841">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6044 href="http://dx.doi.org/10.1158/0008-5472.CAN-09-4245">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d12245e6054 class=n-a></a>Meng MB, Zaorsky NG, Deng L, <i> et al.</i>: Pericytes: a double-edged sword in cancer therapy. <i>Future Oncol.</i> 2015; <b>11</b>(1): 169–79. <a target=xrefwindow id=d12245e6065 href="http://www.ncbi.nlm.nih.gov/pubmed/25143028">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6068 href="http://dx.doi.org/10.2217/fon.14.123">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d12245e6077 class=n-a></a>Tolaney SM, Boucher Y, Duda DG, <i> et al.</i>: Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. <i>Proc Natl Acad Sci U S A.</i> 2015; <b>112</b>(46): 14325–30. <a target=xrefwindow id=d12245e6088 href="http://www.ncbi.nlm.nih.gov/pubmed/26578779">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6091 href="http://dx.doi.org/10.1073/pnas.1518808112">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4655544">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d12245e6104 class=n-a></a>Volz NB, Stintzing S, Zhang W, <i> et al.</i>: Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. <i>Pharmacogenomics J.</i> 2015; <b>15</b>(1): 69–76. <a target=xrefwindow id=d12245e6115 href="http://www.ncbi.nlm.nih.gov/pubmed/25069475">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6118 href="http://dx.doi.org/10.1038/tpj.2014.40">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d12245e6127 class=n-a></a>Kim J, de Sampaio PC, Lundy DM, <i> et al.</i>: Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. <i>JCI Insight.</i> 2016; <b>1</b>(21): e90733. <a target=xrefwindow id=d12245e6138 href="http://www.ncbi.nlm.nih.gov/pubmed/28018977">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6141 href="http://dx.doi.org/10.1172/jci.insight.90733">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6145 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5161212">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d12245e6154 class=n-a></a>Moccia F, Zuccolo E, Poletto V, <i> et al.</i>: Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy. <i>Tumour Biol.</i> 2015; <b>36</b>(9): 6603–14. <a target=xrefwindow id=d12245e6165 href="http://www.ncbi.nlm.nih.gov/pubmed/26232913">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6168 href="http://dx.doi.org/10.1007/s13277-015-3823-2">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727115935"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6177 class=n-a></a>Odent Grigorescu G, Rosca AM, Preda MB, <i> et al.</i>: Synergic effects of VEGF-A and SDF-1 on the angiogenic properties of endothelial progenitor cells. <i>J Tissue Eng Regen Med.</i> 2017; <b>11</b>(11): 3241–3252. <a target=xrefwindow id=d12245e6188 href="http://www.ncbi.nlm.nih.gov/pubmed/27943613">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6191 href="http://dx.doi.org/10.1002/term.2233">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727115935">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d12245e6205 class=n-a></a>Kalathil SG, Lugade AA, Iyer R, <i> et al.</i>: Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. <i>Oncoimmunology.</i> 2016; <b>5</b>(10): e1226718. <a target=xrefwindow id=d12245e6216 href="http://www.ncbi.nlm.nih.gov/pubmed/27853648">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6219 href="http://dx.doi.org/10.1080/2162402X.2016.1226718">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6223 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5087301">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d12245e6232 class=n-a></a>Safarzadeh E, Orangi M, Mohammadi H, <i> et al.</i>: Myeloid-derived Suppressor Cells: important contributors to tumor progression and metastasis. <i>J Cell Physiol.</i> 2018; <b>233</b>(4): 3024–3036. <a target=xrefwindow id=d12245e6243 href="http://www.ncbi.nlm.nih.gov/pubmed/28661031">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6246 href="http://dx.doi.org/10.1002/jcp.26075">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d12245e6255 class=n-a></a>Kumar V, Patel S, Tcyganov E, <i> et al.</i>: The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. <i>Trends Immunol.</i> 2016; <b>37</b>(3): 208–220. <a target=xrefwindow id=d12245e6266 href="http://www.ncbi.nlm.nih.gov/pubmed/26858199">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6269 href="http://dx.doi.org/10.1016/j.it.2016.01.004">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6273 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4775398">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d12245e6282 class=n-a></a>Shojaei F, Wu X, Qu X, <i> et al.</i>: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(16): 6742–7. <a target=xrefwindow id=d12245e6293 href="http://www.ncbi.nlm.nih.gov/pubmed/19346489">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6296 href="http://dx.doi.org/10.1073/pnas.0902280106">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6300 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2665197">Free Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1089815"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6309 class=n-a></a>Shojaei F, Wu X, Malik AK, <i> et al.</i>: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b<sup>+</sup>Gr1<sup>+</sup> myeloid cells. <i>Nat Biotechnol.</i> 2007; <b>25</b>(8): 911–20. <a target=xrefwindow id=d12245e6327 href="http://www.ncbi.nlm.nih.gov/pubmed/17664940">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6330 href="http://dx.doi.org/10.1038/nbt1323">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1089815">F1000 Recommendation</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d12245e6343 class=n-a></a>Du Four S, Maenhout SK, De Pierre K, <i> et al.</i>: Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. <i>Oncoimmunology.</i> 2015; <b>4</b>(4): e998107. <a target=xrefwindow id=d12245e6354 href="http://www.ncbi.nlm.nih.gov/pubmed/26137411">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6357 href="http://dx.doi.org/10.1080/2162402X.2014.998107">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6361 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4485747">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d12245e6371 class=n-a></a>Finke J, Ko J, Rini B, <i> et al.</i>: MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. <i>Int Immunopharmacol.</i> 2011; <b>11</b>(7): 856–61. <a target=xrefwindow id=d12245e6382 href="http://www.ncbi.nlm.nih.gov/pubmed/21315783">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6385 href="http://dx.doi.org/10.1016/j.intimp.2011.01.030">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6389 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3109226">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d12245e6398 class=n-a></a>Rivera LB, Meyronet D, Hervieu V, <i> et al.</i>: Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. <i>Cell Rep.</i> 2015; <b>11</b>(4): 577–91. <a target=xrefwindow id=d12245e6409 href="http://www.ncbi.nlm.nih.gov/pubmed/25892230">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6412 href="http://dx.doi.org/10.1016/j.celrep.2015.03.055">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6416 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4438771">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13408983"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6425 class=n-a></a>Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. <i>Cancer Cell.</i> 2011; <b>20</b>(5): 576–90. <a target=xrefwindow id=d12245e6433 href="http://www.ncbi.nlm.nih.gov/pubmed/22094253">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6436 href="http://dx.doi.org/10.1016/j.ccr.2011.09.009">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6439 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3487108">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13408983">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d12245e6452 class=n-a></a>Peterson JE, Zurakowski D, Italiano JE Jr, <i> et al.</i>: VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. <i>Angiogenesis.</i> 2012; <b>15</b>(2): 265–73. <a target=xrefwindow id=d12245e6463 href="http://www.ncbi.nlm.nih.gov/pubmed/22402885">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6466 href="http://dx.doi.org/10.1007/s10456-012-9259-z">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d12245e6475 class=n-a></a>Walsh TG, Metharom P, Berndt MC: The functional role of platelets in the regulation of angiogenesis. <i>Platelets.</i> 2015; <b>26</b>(3): 199–211. <a target=xrefwindow id=d12245e6483 href="http://www.ncbi.nlm.nih.gov/pubmed/24832135">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6486 href="http://dx.doi.org/10.3109/09537104.2014.909022">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d12245e6495 class=n-a></a>Cao Y: Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. <i>Trends Mol Med.</i> 2013; <b>19</b>(8): 460–73. <a target=xrefwindow id=d12245e6503 href="http://www.ncbi.nlm.nih.gov/pubmed/23773831">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6506 href="http://dx.doi.org/10.1016/j.molmed.2013.05.002">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d12245e6516 class=n-a></a>Radziwon-Balicka A, Moncada de la Rosa C, Jurasz P: Platelet-associated angiogenesis regulating factors: a pharmacological perspective. <i>Can J Physiol Pharmacol.</i> 2012; <b>90</b>(6): 679–88. <a target=xrefwindow id=d12245e6524 href="http://www.ncbi.nlm.nih.gov/pubmed/22512504">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6527 href="http://dx.doi.org/10.1139/y2012-036">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727170006"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6536 class=n-a></a>Di Vito C, Navone SE, Marfia G, <i> et al.</i>: Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release. <i>Platelets.</i> 2017; <b>28</b>(6): 585–594. <a target=xrefwindow id=d12245e6547 href="http://www.ncbi.nlm.nih.gov/pubmed/27897101">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6550 href="http://dx.doi.org/10.1080/09537104.2016.1247208">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727170006">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1149889"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6563 class=n-a></a>Crawford Y, Kasman I, Yu L, <i> et al.</i>: PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. <i>Cancer Cell.</i> 2009; <b>15</b>(1): 21–34. <a target=xrefwindow id=d12245e6574 href="http://www.ncbi.nlm.nih.gov/pubmed/19111878">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6577 href="http://dx.doi.org/10.1016/j.ccr.2008.12.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1149889">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d12245e6590 class=n-a></a>Kinugasa Y, Matsui T, Takakura N: CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. <i>Stem Cells.</i> 2014; <b>32</b>(1): 145–56. <a target=xrefwindow id=d12245e6598 href="http://www.ncbi.nlm.nih.gov/pubmed/24395741">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6601 href="http://dx.doi.org/10.1002/stem.1556">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727104337"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6610 class=n-a></a>Thomas AA, Fisher JL, Hampton TH, <i> et al.</i>: Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. <i>Cancer Immunol Immunother.</i> 2017; <b>66</b>(3): 379–389. <a target=xrefwindow id=d12245e6621 href="http://www.ncbi.nlm.nih.gov/pubmed/27942839">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6624 href="http://dx.doi.org/10.1007/s00262-016-1941-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727104337">F1000 Recommendation</a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d12245e6637 class=n-a></a>Kloepper J, Riedemann L, Amoozgar Z, <i> et al.</i>: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. <i>Proc Natl Acad Sci U S A.</i> 2016; <b>113</b>(16): 4476–81. <a target=xrefwindow id=d12245e6648 href="http://www.ncbi.nlm.nih.gov/pubmed/27044098">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6651 href="http://dx.doi.org/10.1073/pnas.1525360113">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6655 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4843473">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d12245e6665 class=n-a></a>Cicatiello V, Apicella I, Tudisco L, <i> et al.</i>: Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. <i>Oncotarget.</i> 2015; <b>6</b>(12): 10563–76. <a target=xrefwindow id=d12245e6676 href="http://www.ncbi.nlm.nih.gov/pubmed/25868854">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6679 href="http://dx.doi.org/10.18632/oncotarget.3384">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6683 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4496375">Free Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d12245e6692 class=n-a></a>Smirnov IV, Gryazeva IV, Samoilovich MP, <i> et al.</i>: [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors]. <i>Vopr Onkol.</i> 2015; <b>61</b>(6): 898–907. <a target=xrefwindow id=d12245e6703 href="http://www.ncbi.nlm.nih.gov/pubmed/26995976">PubMed Abstract </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d12245e6712 class=n-a></a>Li J, Zhang Z, Lv L, <i> et al.</i>: A bispecific antibody (ScBsAbAgn-2/TSPO) target for Ang-2 and TSPO resulted in therapeutic effects against glioblastomas. <i>Biochem Biophys Res Commun.</i> 2016; <b>472</b>(2): 384–91. <a target=xrefwindow id=d12245e6723 href="http://www.ncbi.nlm.nih.gov/pubmed/26898800">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6726 href="http://dx.doi.org/10.1016/j.bbrc.2016.02.035">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d12245e6735 class=n-a></a>Li JL, Sainson RC, Oon CE, <i> et al.</i>: DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy <i>in vivo</i>. <i>Cancer Res.</i> 2011; <b>71</b>(18): 6073–83. <a target=xrefwindow id=d12245e6749 href="http://www.ncbi.nlm.nih.gov/pubmed/21803743">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6753 href="http://dx.doi.org/10.1158/0008-5472.CAN-11-1704">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d12245e6762 class=n-a></a>Huang J, Hu W, Hu L, <i> et al.</i>: Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. <i>Mol Cancer Ther.</i> 2016; <b>15</b>(6): 1344–52. <a target=xrefwindow id=d12245e6773 href="http://www.ncbi.nlm.nih.gov/pubmed/27009216">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6776 href="http://dx.doi.org/10.1158/1535-7163.MCT-15-0144">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d12245e6785 class=n-a></a>Chiorean EG, LoRusso P, Strother RM, <i> et al.</i>: A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. <i>Clin Cancer Res.</i> 2015; <b>21</b>(12): 2695–703. <a target=xrefwindow id=d12245e6796 href="http://www.ncbi.nlm.nih.gov/pubmed/25724527">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6799 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-2797">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d12245e6809 class=n-a></a>Smith DC, Eisenberg PD, Manikhas G, <i> et al.</i>: A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. <i>Clin Cancer Res.</i> 2014; <b>20</b>(24): 6295–303. <a target=xrefwindow id=d12245e6820 href="http://www.ncbi.nlm.nih.gov/pubmed/25324140">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6823 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-1373">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d12245e6832 class=n-a></a>Bach DH, Kim SH, Hong JY, <i> et al.</i>: Salternamide A Suppresses Hypoxia-Induced Accumulation of HIF-1α and Induces Apoptosis in Human Colorectal Cancer Cells. <i>Mar Drugs.</i> 2015; <b>13</b>(11): 6962–76. <a target=xrefwindow id=d12245e6843 href="http://www.ncbi.nlm.nih.gov/pubmed/26610526">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6846 href="http://dx.doi.org/10.3390/md13116962">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6850 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4663561">Free Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d12245e6859 class=n-a></a>Falchook GS, Wheler JJ, Naing A, <i> et al.</i>: Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. <i>Oncotarget.</i> 2014; <b>5</b>(21): 10280–92. <a target=xrefwindow id=d12245e6870 href="http://www.ncbi.nlm.nih.gov/pubmed/25373733">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6873 href="http://dx.doi.org/10.18632/oncotarget.2163">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6877 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4279372">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d12245e6886 class=n-a></a>Jeong W, Park SR, Rapisarda A, <i> et al.</i>: Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. <i>Invest New Drugs.</i> 2014; <b>32</b>(2): 340–6. <a target=xrefwindow id=d12245e6897 href="http://www.ncbi.nlm.nih.gov/pubmed/24242862">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6900 href="http://dx.doi.org/10.1007/s10637-013-0048-3">Publisher Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d12245e6909 class=n-a></a>Di Desidero T, Xu P, Man ST, <i> et al.</i>: Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. <i>Oncotarget.</i> 2015; <b>6</b>(40): 42396–410. <a target=xrefwindow id=d12245e6920 href="http://www.ncbi.nlm.nih.gov/pubmed/26623560">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6923 href="http://dx.doi.org/10.18632/oncotarget.6377">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6927 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4767441">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d12245e6936 class=n-a></a>Yin T, He S, Shen G, <i> et al.</i>: HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model. <i>Oncol Res.</i> 2014; <b>22</b>(3): 139–45. <a target=xrefwindow id=d12245e6947 href="http://www.ncbi.nlm.nih.gov/pubmed/26168132">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6950 href="http://dx.doi.org/10.3727/096504014X13983417587366">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725442692"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6960 class=n-a></a>Postow MA, Chesney J, Pavlick AC, <i> et al.</i>: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>N Engl J Med.</i> 2015; <b>372</b>(21): 2006–17. <a target=xrefwindow id=d12245e6971 href="http://www.ncbi.nlm.nih.gov/pubmed/25891304">PubMed Abstract </a> | <a target=xrefwindow id=d12245e6974 href="http://dx.doi.org/10.1056/NEJMoa1414428">Publisher Full Text </a> | <a target=xrefwindow id=d12245e6978 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5744258">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725442692">F1000 Recommendation</a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725442696"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e6991 class=n-a></a>Robert C, Schachter J, Long GV, <i> et al.</i>: Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>N Engl J Med.</i> 2015; <b>372</b>(26): 2521–32. <a target=xrefwindow id=d12245e7002 href="http://www.ncbi.nlm.nih.gov/pubmed/25891173">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7005 href="http://dx.doi.org/10.1056/NEJMoa1503093">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725442696">F1000 Recommendation</a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727504006"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e7018 class=n-a></a>Schmittnaegel M, Rigamonti N, Kadioglu E, <i> et al.</i>: Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. <i>Sci Transl Med.</i> 2017; <b>9</b>(385): pii: eaak9670. <a target=xrefwindow id=d12245e7029 href="http://www.ncbi.nlm.nih.gov/pubmed/28404865">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7032 href="http://dx.doi.org/10.1126/scitranslmed.aak9670">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727504006">F1000 Recommendation</a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727504004"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e7045 class=n-a></a>Allen E, Jabouille A, Rivera LB, <i> et al.</i>: Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. <i>Sci Transl Med.</i> 2017; <b>9</b>(385): pii: eaak9679. <a target=xrefwindow id=d12245e7056 href="http://www.ncbi.nlm.nih.gov/pubmed/28404866">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7059 href="http://dx.doi.org/10.1126/scitranslmed.aak9679">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7063 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5554432">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727504004">F1000 Recommendation</a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d12245e7076 class=n-a></a>Hughes PE, Caenepeel S, Wu LC: Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. <i>Trends Immunol.</i> 2016; <b>37</b>(7): 462–76. <a target=xrefwindow id=d12245e7084 href="http://www.ncbi.nlm.nih.gov/pubmed/27216414">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7087 href="http://dx.doi.org/10.1016/j.it.2016.04.010">Publisher Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726580524"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e7096 class=n-a></a>Nguyen L, Fifis T, Christophi C: Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. <i>BMC Cancer.</i> 2016; <b>16</b>: 533. <a target=xrefwindow id=d12245e7104 href="http://www.ncbi.nlm.nih.gov/pubmed/27460820">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7107 href="http://dx.doi.org/10.1186/s12885-016-2568-7">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7110 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4962549">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726580524">F1000 Recommendation</a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d12245e7124 class=n-a></a>Gerstner ER, Ye X, Duda DG, <i> et al.</i>: A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro Oncol.</i> 2015; <b>17</b>(10): 1386–92. <a target=xrefwindow id=d12245e7135 href="http://www.ncbi.nlm.nih.gov/pubmed/26008604">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7138 href="http://dx.doi.org/10.1093/neuonc/nov085">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4578584">Free Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d12245e7151 class=n-a></a>Reynolds AR, Hart IR, Watson AR, <i> et al.</i>: Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. <i>Nat Med.</i> 2009; <b>15</b>(4): 392–400. <a target=xrefwindow id=d12245e7162 href="http://www.ncbi.nlm.nih.gov/pubmed/19305413">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7165 href="http://dx.doi.org/10.1038/nm.1941">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1127019"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e7174 class=n-a></a>Caswell PT, Chan M, Lindsay AJ, <i> et al.</i>: Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. <i>J Cell Biol.</i> 2008; <b>183</b>(1): 143–55. <a target=xrefwindow id=d12245e7185 href="http://www.ncbi.nlm.nih.gov/pubmed/18838556">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7188 href="http://dx.doi.org/10.1083/jcb.200804140">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7192 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2557049">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1127019">F1000 Recommendation</a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d12245e7205 class=n-a></a>Nakazawa Y, Kawano S, Matsui J, <i> et al.</i>: Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model. <i>Cancer Sci.</i> 2015; <b>106</b>(2): 201–7. <a target=xrefwindow id=d12245e7216 href="http://www.ncbi.nlm.nih.gov/pubmed/25458359">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7219 href="http://dx.doi.org/10.1111/cas.12581">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7223 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4399030">Free Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d12245e7232 class=n-a></a>Manzat Saplacan RM, Balacescu L, Gherman C, <i> et al.</i>: The Role of PDGFs and PDGFRs in Colorectal Cancer. <i>Mediators Inflamm.</i> 2017; <b>2017</b>: 4708076. <a target=xrefwindow id=d12245e7243 href="http://www.ncbi.nlm.nih.gov/pubmed/28163397">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7246 href="http://dx.doi.org/10.1155/2017/4708076">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7250 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5259650">Free Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13489040"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e7259 class=n-a></a>Cooke VG, LeBleu VS, Keskin D, <i> et al.</i>: Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. <i>Cancer Cell.</i> 2012; <b>21</b>(1): 66–81. <a target=xrefwindow id=d12245e7270 href="http://www.ncbi.nlm.nih.gov/pubmed/22264789">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7273 href="http://dx.doi.org/10.1016/j.ccr.2011.11.024">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7277 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3999522">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13489040">F1000 Recommendation</a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d12245e7291 class=n-a></a>Keskin D, Kim J, Cooke VG, <i> et al.</i>: Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. <i>Cell Rep.</i> 2015; <b>10</b>(7): 1066–81. <a target=xrefwindow id=d12245e7302 href="http://www.ncbi.nlm.nih.gov/pubmed/25704811">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7305 href="http://dx.doi.org/10.1016/j.celrep.2015.01.035">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7309 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4342328">Free Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d12245e7318 class=n-a></a>Chung SW, Bae SM, Lee M, <i> et al.</i>: LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways. <i>Biomaterials.</i> 2015; <b>37</b>: 271–8. <a target=xrefwindow id=d12245e7329 href="http://www.ncbi.nlm.nih.gov/pubmed/25453957">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7332 href="http://dx.doi.org/10.1016/j.biomaterials.2014.10.004">Publisher Full Text </a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a name=d12245e7341 class=n-a></a>Kim JY, Chung SW, Kim SY, <i> et al.</i>: Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor. <i>Pharm Res.</i> 2015; <b>32</b>(7): 2318–27. <a target=xrefwindow id=d12245e7352 href="http://www.ncbi.nlm.nih.gov/pubmed/25585956">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7355 href="http://dx.doi.org/10.1007/s11095-015-1623-4">Publisher Full Text </a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727121247"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12245e7364 class=n-a></a>Guffanti F, Chilà R, Bello E, <i> et al.</i>: <i>In Vitro</i> and <i>In Vivo</i> Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models. <i>Neoplasia.</i> 2017; <b>19</b>(1): 35–42. <a target=xrefwindow id=d12245e7382 href="http://www.ncbi.nlm.nih.gov/pubmed/27988457">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7385 href="http://dx.doi.org/10.1016/j.neo.2016.11.008">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5167242">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727121247">F1000 Recommendation</a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a name=d12245e7401 class=n-a></a>Kienast Y, Klein C, Scheuer W, <i> et al.</i>: Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. <i>Clin Cancer Res.</i> 2013; <b>19</b>(24): 6730–40. <a target=xrefwindow id=d12245e7412 href="http://www.ncbi.nlm.nih.gov/pubmed/24097868">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7415 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0081">Publisher Full Text </a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a name=d12245e7424 class=n-a></a>Koh YJ, Kim HZ, Hwang SI, <i> et al.</i>: Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. <i>Cancer Cell.</i> 2010; <b>18</b>(2): 171–84. <a target=xrefwindow id=d12245e7435 href="http://www.ncbi.nlm.nih.gov/pubmed/20708158">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7438 href="http://dx.doi.org/10.1016/j.ccr.2010.07.001">Publisher Full Text </a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d12245e7448 class=n-a></a>Ruan J, Luo M, Wang C, <i> et al.</i>: Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood.</i> 2013; <b>121</b>(26): 5192–202. <a target=xrefwindow id=d12245e7459 href="http://www.ncbi.nlm.nih.gov/pubmed/23632889">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7462 href="http://dx.doi.org/10.1182/blood-2013-03-490763">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7466 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3695363">Free Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d12245e7475 class=n-a></a>Liontos M, Lykka M, Dimopoulos MA, <i> et al.</i>: Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. <i>Onco Targets Ther.</i> 2014; <b>7</b>: 1837–45. <a target=xrefwindow id=d12245e7486 href="http://www.ncbi.nlm.nih.gov/pubmed/25336975">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7489 href="http://dx.doi.org/10.2147/OTT.S65522">Publisher Full Text </a> | <a target=xrefwindow id=d12245e7493 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4199819">Free Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d12245e7502 class=n-a></a>Johnson PJ, Qin S, Park JW, <i> et al.</i>: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. <i>J Clin Oncol.</i> 2013; <b>31</b>(28): 3517–24. <a target=xrefwindow id=d12245e7513 href="http://www.ncbi.nlm.nih.gov/pubmed/23980084">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7516 href="http://dx.doi.org/10.1200/JCO.2012.48.4410">Publisher Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d12245e7525 class=n-a></a>Llovet JM, Decaens T, Raoul JL, <i> et al.</i>: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. <i>J Clin Oncol.</i> 2013; <b>31</b>(28): 3509–16. <a target=xrefwindow id=d12245e7536 href="http://www.ncbi.nlm.nih.gov/pubmed/23980090">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7539 href="http://dx.doi.org/10.1200/JCO.2012.47.3009">Publisher Full Text </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a name=d12245e7548 class=n-a></a>Gao DY, Lin TsT, Sung YC, <i> et al.</i>: CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. <i>Biomaterials.</i> 2015; <b>67</b>: 194–203. <a target=xrefwindow id=d12245e7559 href="http://www.ncbi.nlm.nih.gov/pubmed/26218745">PubMed Abstract </a> | <a target=xrefwindow id=d12245e7562 href="http://dx.doi.org/10.1016/j.biomaterials.2015.07.035">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 15 Mar 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-326.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-326.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>2</sup> Reproductive Medicine Research Center, Department of Gynecology and Obstetrics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong province, China<br/> <sup>3</sup> Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>4</sup> Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <p> <div class=margin-bottom> Shaolin Ma <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Sunila Pradeep <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Wei Hu <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Dikai Zhang <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Robert Coleman <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Anil Sood <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-326/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 15 Mar 2018, 7:326 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11771.1">https://doi.org/10.12688/f1000research.11771.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Ma S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12716 data-id=11771 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11771.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-326/v1/pdf?article_uuid=1fb7effe-a190-42fc-ab40-6ba735f025f1" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11771.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ma S, Pradeep S, Hu W <em>et al.</em> The role of tumor microenvironment in resistance to anti-angiogenic therapy [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):326 (<a href="https://doi.org/10.12688/f1000research.11771.1" target=_blank>https://doi.org/10.12688/f1000research.11771.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11771 id=mobile-track-article-signin-11771 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11771?target=/articles/7-326.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12716 /> <input name=articleId type=hidden value=11771 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Miguel Quintela-Fandino</strong>, Breast Cancer Clinical Research Unit, CNIO-Spanish National Research Cancer Centre, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Andrew Reynolds</strong>, Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 15 Mar 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-326.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-326.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=31563-31676></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=1180-31677></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-326/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>15 Mar 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Miguel Quintela-Fandino</strong>, Breast Cancer Clinical Research Unit, CNIO-Spanish National Research Cancer Centre, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Andrew Reynolds</strong>, Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-326.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-326/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "The role of tumor microenvironment in resistance...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-326/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-326/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-326/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ma S et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-326/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-326",
            templates : {
                twitter : "The role of tumor microenvironment in resistance to anti-angiogenic.... Ma S et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-326/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: The role of tumor microenvironment in resistance to anti-angiogenic therapy", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: The role of tumor microenvironment in resistance to anti-angiogenic therapy", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11771/12716")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12716");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "31676": 0,
                           "31677": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "7fb96c8c-5761-440f-b187-47c378240852";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-326.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-326.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-326.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-326.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-326.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>